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Abstract
X-ray computed tomography (CT) is one of the most widely used clinical imaging modalities, and recent
developments in CT detectors and reconstruction methods are fueling its rapid innovation and expansion
of its diagnostic values. However, despite the advancement in nanotechnology and nanoparticle-based
contrast agents, small molecule-based iodinated contrast agents with several drawbacks, such as short
blood half-lives, low CT contrast generation at high tube potential, and potential adverse effects, remain to
be the only FDA approved CT contrast agents for intravascular administration. Development of novel
nanoparticle-based CT contrast agents will not only resolve these drawbacks, but also facilitate the
emergence of new CT technologies, such as photon-counting CT (SPCCT), and novel CT imaging
applications. In this thesis, we present the development of nanoparticles that are specifically designed for
numerous CT and SPCCT imaging applications. Sub-5 nm tantalum oxide nanoparticles (TaONP) were
developed after investigating CT contrast generation properties and material differentiation of several
candidate elements for SPCCT-specific contrast agent. To prolong blood circulation time and improve CT
contrast production, TaONP were encapsulated in polymeric nanoparticles along with other sub-5 nm
nanoparticles made of cerium (CeONP) and gold (AuNP). These polymeric nanoparticles produced
consistently high CT attenuation across multiple clinical settings and were efficiently degraded into small
nanoparticles within 7 days in biological fluids. Our CT contrast generation results also revealed that
CeONP were able to produce higher CT contrast when compared to other experimental contrast agents
especially at low tube potentials. Understanding that CeONP can also have immunomodulatory
properties, we further investigated them as both CT contrast agents and therapeutic agents for targeted
imaging and treatment of inflammatory diseases, expanding the potential CT imaging applications.
Moreover, 85 % of the injected dose were excreted within 24 hours of intravenous injection, indicating
CeONP’s feasibility of clinical translation. To further expand the CT imaging applications to cell tracking,
sub-5 nm AuNP were encompassed in lipid-based transfection reagents to label chimeric antigen receptor
(CAR)-T cells to monitor their behavior in cancer immunotherapy against solid tumors. This work
highlights key considerations in the development of CT and SPCCT-specific contrast agents and the
potential use of nanoparticle-based contrast agents for broadening CT and SPCCT imaging applications.
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ABSTRACT

DEVELOPMENT OF NANOPARTICLE-BASED CONTRAST AGENTS FOR
APPLICATIONS WITH CONVENTIONAL AND PHOTON-COUNTING CT IMAGING
Johoon Kim
David P. Cormode

X-ray computed tomography (CT) is one of the most widely used clinical imaging
modalities, and recent developments in CT detectors and reconstruction methods are
fueling its rapid innovation and expansion of its diagnostic values. However, despite the
advancement in nanotechnology and nanoparticle-based contrast agents, small moleculebased iodinated contrast agents with several drawbacks, such as short blood half-lives,
low CT contrast generation at high tube potential, and potential adverse effects, remain to
be the only FDA approved CT contrast agents for intravascular administration.
Development of novel nanoparticle-based CT contrast agents will not only resolve these
drawbacks, but also facilitate the emergence of new CT technologies, such as photoncounting CT (SPCCT), and novel CT imaging applications. In this thesis, we present the
development of nanoparticles that are specifically designed for numerous CT and SPCCT
imaging applications. Sub-5 nm tantalum oxide nanoparticles (TaONP) were developed
after investigating CT contrast generation properties and material differentiation of several
candidate elements for SPCCT-specific contrast agent. To prolong blood circulation time
and improve CT contrast production, TaONP were encapsulated in polymeric
nanoparticles along with other sub-5 nm nanoparticles made of cerium (CeONP) and gold
(AuNP). These polymeric nanoparticles produced consistently high CT attenuation across
iii

multiple clinical settings and were efficiently degraded into small nanoparticles within 7
days in biological fluids. Our CT contrast generation results also revealed that CeONP
were able to produce higher CT contrast when compared to other experimental contrast
agents especially at low tube potentials. Understanding that CeONP can also have
immunomodulatory properties, we further investigated them as both CT contrast agents
and therapeutic agents for targeted imaging and treatment of inflammatory diseases,
expanding the potential CT imaging applications. Moreover, 85 % of the injected dose
were excreted within 24 hours of intravenous injection, indicating CeONP’s feasibility of
clinical translation. To further expand the CT imaging applications to cell tracking, sub-5
nm AuNP were encompassed in lipid-based transfection reagents to label chimeric
antigen receptor (CAR)-T cells to monitor their behavior in cancer immunotherapy against
solid tumors. This work highlights key considerations in the development of CT and
SPCCT-specific contrast agents and the potential use of nanoparticle-based contrast
agents for broadening CT and SPCCT imaging applications.
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CHAPTER 1: INTRODUCTION TO APPLICATIONS OF NANOPARTICLEBASED CONTRAST AGENTS FOR CT IMAGING AND OTHER
BIOMEDICAL APPLICATIONS
1.1 Introduction
Advances in nanotechnology have allowed us to synthesize particle structures that
are nanometers in size, called nanoparticles. It is also feasible to precisely control their
physical and chemical properties and to make them stable and biocompatible for use in a
range of biomedical applications. These applications include, but are not limited to,
delivery of drug and genetic materials, sensitizers for photothermal and radiotherapy,
contrast agents for medical imaging, and substitutes for traditional enzymes.
One field of wide interest for nanoparticle application is in development of contrast
agents for X-ray computed tomography (CT), which is one of the most commonly used
clinical imaging modalities. Its advantages of high spatial resolution and capabilities in
quantitative analyses motivated the emergence of new CT techniques, such as photoncounting CT (SPCCT) that can allow material differentiation, and use of CT imaging for
numerous imaging applications, such as cell tracking. Combined with the advances in
nanoparticle sciences, CT imaging applications are also being expanded to the field of
targeted and molecular imaging.
Herein, we propose and develop nanoparticles that are specifically designed for
various CT and SPCCT imaging-based applications, ranging from contrast agents, cell
tracking probes for cancer immunotherapy, and a theranostic agent for inflammatory
diseases. These nanoparticles are made of various heavy metals and are coated with
different types of polymers, lipids, and small molecules. The materials as well as the
physiochemical properties (i.e., size and surface potential) of the nanoparticles were
selected and designed to be suitable for their respective applications. In development of
1

SPCCT contrast agents, we screened several candidate elements, considered their safety,
cost, K-edge energies and others, and developed an ultrasmall nanoparticle formulation
made of tantalum that showed high contrast generation in both CT and SPCCT imaging
(Chapter 2). We also synthesized a polymer-based large nanoparticle formulation that
encapsulates ultrasmall nanoparticles made of three different elements. This nanoparticle
design will allow prolonged blood circulation, followed by eventual renal clearance as the
polymer degrades to release the small nanoparticles. Inclusion of three different elements
whose K-edge energies are spread out in the photon energy spectra used in clinical
settings also led to high CT contrast generation in numerous CT scanning parameters
used in clinical imaging (Chapter 3).
Instead of using nanoparticles as contrast agents for whole-body or tissue-specific
imaging applications, we investigated a method to use the nanoparticles to label specific
cells in cell-based therapy. For this, we developed gold nanoparticles that are
encapsulated by lipid-based transfection reagents to promote ex vivo labeling of CAR-T
cells, and thus allowing CAR-T cell tracking in cancer immunotherapy (Chapter 4). Some
nanoparticle formulations, such as cerium oxide nanoparticles, are also known to have
catalytic properties that can be exploited for therapeutic benefits. Therefore, we examined
cerium oxide nanoparticles’ potential use for both CT imaging and immunomodulation in
acute inflammation (Chapter 5).

1.2 Background
1.2.1 X-ray computed tomography
CT is an X-ray based medical imaging technique that was first brought into clinical
use in the 1970s.1 CT imaging is now being widely used for diagnosis and monitoring of
2

numerous medical conditions such as trauma, cancer, cardiovascular diseases, and
gastrointestinal disorders. Its quick image acquisition time and wide clinical availability
also allowed it to be extensively used in emergency medicine. CT is currently undergoing
a period of rapid innovation. More powerful algorithms such as iterative reconstruction and
model-based iterative reconstruction have been developed for improved image quality.2-5
The speed of image acquisition is being further improved, and new innovations such as
dual energy CT systems that can provide spectral information in the image have also
become available.

1.2.1.1 CT principles
A typical CT scanner has an X-ray source that emits a beam of photons toward the
opposite side of the scanner where an array of detector modules is positioned to absorb
transmitted X-ray photons that are not absorbed or scattered by the subject. CT images
are typically acquired by placing the subject placed on a bed that moves into the scanner
as the source and the detector rotate around the subject to collect 360° data sets.
X-rays are generated in the source when electrons accelerated from a cathode
collide with a metal anode, resulting in Bremsstrahlung and characteristic radiation. For
Bremsstrahlung radiation, the accelerated electrons interact with the nuclei of the anode
and lose some of their kinetic energy via X-ray photon emission (Figure 1.1A). In
characteristic radiation, the incident electron collides and ejects an inner electron of the
anode atom. Subsequently, an electron from an outer orbital fills the vacancy while
emitting some of its energy as an X-ray photon (Figure 1.1B). Due to the fixed energy
difference between the outer orbitals and the inner orbital, this results in sharp peaks in
the X-ray spectrum (Figure 1.1C).

3

Figure 1.1 Sources of X-ray generation.
Schematic depictions of (A) Bremsstrahlung radiation and (B) characteristic radiation. (C)
Typical photon energy spectrum emitted from a CT scanner. Reproduced with permission
from Lee et al.6

The X-rays emitted from the tube are directed at the subject where some of the
beam is absorbed and scattered, while the remainder continues toward the detector. The
loss of X-ray intensity from absorption and scattering by the patient is referred to as X-ray
attenuation. X-rays are attenuated by three types of interactions, namely, Compton
scattering, the photoelectric effect, and coherent scattering. At the typical energy levels
used in CT scans (~25 to 150 keV), the photoelectric effect and Compton scattering are
the two main forms of interactions that cause attenuation.6,

7

The photoelectric effect

occurs when incident X-rays collide and transfer their energies to inner shell electrons (K-

4

shell or L-shell) of atoms that constitute the subject, ejecting them from the atom as a
result (Figure 1.2A).

Figure 1.2 Sources of X-ray attenuation.
Schematic depictions of (A) the photoelectric effect and (B) Compton scattering.
Reproduced with permission from Danad et al.8

An electron from the outer electron shell then fills the vacancy and releases a
photon, whose energy is characteristic to the atom. The probability of the occurrence of
photoelectric effect is generally proportional to Z3 (Z = atomic number), explaining the
considerable research interest in developing CT contrast agents based on high-Z
elements. Note that the photoelectric effect can only occur above the binding energy of
the K-shell electrons. In addition, the probability of such an event is maximal at the energy
5

of the K-shell and declines as the energy increases beyond the K-shell, creating features
in element X-ray attenuation spectra known as K-edge (Figure 1.3). In Compton scattering,
incident X-ray photons interact with weakly bound electrons in the outer shell, lose some
of their energy, and are deflected from their original path with reduced energy (Figure
1.2B). The deflection from their original path, as well as the need for collimation at the
detectors, mean that Compton scattering is a cause of attenuation. Since Compton
scattering occurs between photons and outer electrons, it is primarily affected by the
electron density of the atom.6

Figure 1.3 K-edge energies of various elements.
Mass attenuation coefficients of various elements where the K-edges are clearly apparent
(spikes in the attenuation coefficient curves at certain energies indicated by down arrows).
Figure reproduced with permission from Cormode et al.7

CT attenuation is given in Hounsfield units (HU). For a given material X, HU =
1000(μX − μwater)/(μair − μwater) where μ is the attenuation coefficient. Air therefore has a CT
attenuation of −1000 HU and the attenuation of water is 0 HU. The attenuation of bone
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ranges from 400 to 1000 HU, and most soft tissues have attenuation of about 40 to 80
HU.7 The energies and number of X-ray photons in the beam mainly depend on the
maximum tube voltage and electric current used. The maximum photon energy is
equivalent to the maximum tube voltage, and the number of photons is inversely
proportional to the energy (except at the characteristic energies of the anode material).
However, low-energy X-ray photons are easily absorbed in the anode and filters,
eliminating X-rays in the 0−25 keV range and reducing the number of X-rays in the 25−50
keV range (Figure 1.1C). In addition, absorption of lower energy photons within the patient
can occur, creating an effect known as beam hardening. Once the X-ray beam reaches
the detectors, most of the scattered X-ray photons are absorbed in the collimator in front
of the detector and X-ray radiation of diagnostic value is absorbed and converted to light
in scintillator. The converted light energy in each pixel of the scintillator is then converted
into electronic current, which is transmitted as digital output data. From the transmitted
data, CT images are reconstructed using computer algorithms. Filtered back-projection
algorithms have traditionally been used for reconstruction. However, with recent
advancements in computing power, iterative reconstruction methods have been applied,
which result in noise reduction and hence improvement in sensitivity (Figure 1.4).9, 10

Figure 1.4 CT image reconstruction techniques.
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Images of coronary computed tomography angiography of the right coronary artery
reconstructed with (A) filtered back projection, (B) hybrid iterative reconstruction (iDose4),
and (C) iterative model-based reconstruction. The white arrow points at the right coronary
artery, and the white arrowhead points at a noncalcified plaque. The images demonstrate
noise reduction of iterative reconstruction when compared to filtered back projection.
Figure reproduced with permission from Halpern et al.9

Post-processing parameters including windowing, slice thickness, and field of view
can be adjusted to give optimal image appearance and spatial resolution.11 Recent
improvements in detector rows, gantry rotation speed, reconstruction methods, and 3D
rendering image processing make CT a powerful tool for diagnostic purposes.
Furthermore, recently developed CT systems that use photon-counting detectors can
provide energy resolution of the transmitted photons, which allows differentiation of
multiple tissues and exogenous contrast agents (Figure 1.5).12-14 In order to provide more
information in CT imaging, contrast agents are often used. With the photoelectric effect
and K-edge attenuation taken into consideration, elements with high atomic numbers and
appropriate K-edge energies (i.e., K-edges where there are high numbers of photons in
the energy distribution in Figure 1.1C) have good potential to be used as CT contrast
agents.
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Figure 1.5 Material differentiation in SPCCT imaging.
(A) Conventional CT image of an artery phantom. (B) Gold, iodine, photoelectric, and
Compton images of the phantom and an overlay of all four images acquired by spectral
CT imaging. Figure reproduced with permission from Cormode et al.12

1.2.1.2 Spectral photon counting CT technology
The detectors in conventional CT scanner are known as energy-integrating
detectors (EIDs), in which all of the energy deposited in each pixel is summed and is
transmitted as a single signal. This leads to omission of any energy-dependent information
of individual X-ray photons and heavier weighting of higher energy photons, which carry
less information on soft tissue contrast. Since CT attenuation is dependent on the mass
density and atomic number of the material, materials of different elemental compositions
and varying concentrations can produce identical CT attenuation values in EIDs, making
differentiation of such materials extremely difficult.
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One example of a clinical scenario that could benefit from material differentiation
is separation of calcified plaques from the lumen of iodine-filled blood vessels. Calcium
deposits within vulnerable atherosclerotic plaques and bones near plaque sites not only
obscure the lumen anatomy, but can also generate similar CT attenuation as iodine-filled
blood vessels to hinder clear visualization of the plaques, increasing the chance of
misdiagnoses. Material differentiation imaging methods that can resolve such issues are
highly attractive. One method that allows material differentiation is dual energy CT (DECT)
imaging. The principle of DECT is to acquire two sets of CT data using two different energy
spectra. This idea was first introduced and demonstrated in the 1970s, although the speed
of image acquisition at that time was not sufficient for clinical implementation. Since then,
multiple approaches have been developed for clinical use, such as slow kVp switching,
rapid kVp switching, and using multilayer detectors or dual X-ray sources.15 DECT
techniques are FDA approved, and clinical CT scanners with two energy spectra are
commercially available.16 Many clinical applications of DECT also have been studied,
including virtual monoenergetic imaging for optimal contrast-to-noise ratio (CNR) of iodine,
bone removal in CT angiography, and virtual non-contrast enhanced images.15, 17
However, DECT techniques still have several limitations including susceptibility to
motion, high overlap of energy spectra, and high noise levels in low-energy data. All of
these restraints can cause degradation in image quality and inaccurate material
differentiation. Moreover, in some forms of DECT, there is increased radiation dose to the
patient, since two X-ray tubes are used to scan. A rapidly emerging CT technology, called
spectral photon counting CT (SPCCT), that can overcome the limitations of DECT systems
is currently under extensive investigation for its clinical feasibility. Since its first evaluation
in preclinical CT systems about a decade ago, the latest prototypes of SPCCT scanners
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have evolved to be based on modified clinical CT systems.18 SPCCT uses a standard
polychromatic X-ray source and photon-counting detectors (PCDs) that can potentially
provide more accurate material decomposition (Figure 1.6). PCDs are composed of
semiconductor materials such as cadmium zinc telluride or silicon. When an X-ray photon
is absorbed by these detectors, electron hole pairs are formed, resulting in a charge cloud
and current pulse whose magnitude is proportional to the photon energy. The magnitude
of each current pulse is measured by the electronics and each X-ray photon event is
recorded in one of several energy bins. The number of bins and their energy thresholds
can be adjusted for user-specific applications (e.g., near the K-edge of the specific
material of interest) (Figure 1.6).19

Figure 1.6 Schematic depiction of an SPCCT system.
The binned data may be used to generate different types of image sets such as those
listed (i.e., synthesized conventional CT images and iodine, water, and gold material
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specific images) or other sets of images. Figure adapted with permission from Cormode
et al.20

These data sets are then processed together to provide a set of images, which
typically include a conventional image and material-specific images (e.g., water, iodine,
and gold) (Figure 1.6). SPCCT systems have several benefits, such as lower noise levels,
improved CNR and spectral separation, higher spatial resolution, fewer image artifacts,
and increased geometric and dose efficiency.14, 21, 22 Another benefit of SPCCT imaging is
that they can provide absolute quantification of exogeneous contrast agents in vivo, which
can be utilized in targeted or molecular imaging.18 Recent studies have demonstrated the
feasibility of differentiating multiple materials in both small and large animals.12, 23, 24 In
addition, the clinical emergence of SPCCT technology has been embraced by multiple
studies demonstrating comparable image quality between conventional CT and SPCCT
scanners in terms of noise levels and CNR.25-28

1.2.2 Nanoparticle contrast agents for CT and SPCCT imaging
1.2.2.1 Iodinated contrast agents
The most commonly used CT contrast agent in contrast-enhanced CT imaging are
small molecule-based iodinated contrast agents, such as iopamidol or iodixanol.29
However, they are numerous drawbacks, such as short blood half-lives, non-specificity,
and low CT contrast generation at high tube potential imaging. Moreover, these contrast
agents are known to cause further reduction in kidney function in patients with renal
insufficiency through contrast-induced nephropathy (CIN).16,

30, 31

Contrast-induced

abnormalities result in morbidity, mortality, and cost. The numbers of populations with
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cardiovascular diseases and renal insufficiency are both growing and are expected to
grow continuously.32 Thus, there is a compelling need to develop novel CT contrast
agents.

1.2.2.2 Nanoparticle-based CT contrast agents
Despite the disadvantages of iodinated contrast agents, there has not been a new
CT contrast agent clinically approved for over 20 years. The development of nanoparticle
contrast agents can effectively overcome the issues of iodinated small molecules
Nanoparticles of 3 nm, for example, could contain hundreds of contrast generating atoms,
which would place a lower burden on the kidneys since far few excretion events would be
needed. Alternatively, nanoparticles can be designed to erode slowly, resulting in gradual
release of their payload for excretion, minimizing the concentration at the kidneys at any
given time.33, 34 Nanoparticles made of dense, heavy metals with high payloads have been
the focus of novel nanoparticle CT contrast agent development to overcome the low
sensitivity of CT. These nanoparticles are often designed to be less than 6 nm in
hydrodynamic diameter to lower the body retention and thus to increase their potential for
clinical translation. Most reported nanoparticles are approximately spherical, but they can
have many other shapes, such as rods,35 cages,36 or stars.37 The shape of a nanoparticle
can strongly influence its properties; for example, the shape of a gold nanoparticle can
determine its suitability for applications such as optical imaging or surface enhanced
Raman spectroscopy,35, 38, 39 although shape should not affect CT contrast generation.
Nanoparticle CT contrast agents typically consist of a core loaded with contrast
generating atoms, which is coated with polymers, lipids, proteins, silica, or other
compounds that can provide the desired circulation times, biodistribution, stability and
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solubility in biological media, and biocompatibility. The coating layers can also be easily
modified to incorporate other functionalities, such as target specificity with antibodies,
therapeutic effects via drugs or genetic materials, or multimodal imaging capacity with
other contrast generating moieties.40, 41 Nanoparticles may therefore also be synthesized
to possess desired properties and to provide versatility and multifunctionality. 42 Lipidbased structures (liposomes,

emulsions, micelles, or lipoproteins) and solid core

nanoparticles (metal, metal alloy, or metal salt) or combinations of the two are the most
frequently studied formations for CT applications.43, 44 For metal core-based agents, gold
nanoparticles have been the most extensively studied as CT contrast agents, due to gold’s
high atomic number of 79 and K-edge at 80.7 keV, its excellent biocompatibility,
bioinertness, synthetic control over size and shape, as well as ease of surface
modification.45,

46

Other heavy metal elements, such as bismuth, tantalum, platinum,

ytterbium, yttrium, gadolinium, and tungsten, have also been studied.7, 47, 48
Nanoparticles are widely studied for vascular imaging as blood pool CT contrast
agents since they can be engineered to have long circulation times.43, 48 They have also
garnered significant research interest for cancer imaging via both passive and active
targeting. By conjugating various targeting moieties to nanoparticles, targeted imaging of
lymph nodes and cardiovascular diseases have been previously demonstrated.49
Nanoparticle CT contrast agents can also be used for concurrent diagnosis and therapy
by loading therapeutic cargoes or by exploitation of inherent therapeutic properties, such
as photothermal ablation using gold nanorods and reduction of oxidative stress using
cerium oxide nanoparticles.50, 51
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1.2.2.3 Nanoparticle-based SPCCT contrast agents
Nanoparticle-based contrast agents also have high potential to be developed as
contrast agents for SPCCT imaging, which is an area in SPCCT imaging that can
significantly contribute to the improvement of diagnostic quality of SPCCT images. While
iodine-based contrast agents provide sufficient contrast in both single energy CT and
DECT imaging, they suffer from low contrast generation at higher X-ray tube potentials
that are needed for large adults (e.g., 140 kVp). Moreover, they do not take full advantage
of the robust material decomposition capabilities of SPCCT imaging because of iodine’s
low K-edge energy (33.2 keV). Most photons whose energy levels are lower than or near
the K-edge energy of iodine are absorbed by the filter and the patient. For this reason,
there are not enough photons in transmitted X-ray spectra below iodine’s K-edge energy
for accurate K-edge imaging. Novel SPCCT contrast agents will need to be specifically
designed for the imaging technique in order to overcome the limitations of iodinated
contrast agents.
In the development of a novel SPCCT contrast agent, several important factors
need to be considered. These considerations include safety, manufacturing cost and
availability, and the K-edge of the element. A majority of the studies that have investigated
SPCCT-specific contrast agent development have focused on gadolinium, ytterbium,
tantalum, tungsten, gold, and bismuth, which are some of the elements that satisfy the
aforementioned considerations.12, 20, 52-55 Other elements that have also been explored
include hafnium for its appropriate K-edge energy in the clinical X-ray energy spectra,
despite its largely unknown safety profile.56, 57 Recent studies have demonstrated that
these heavy metal elements perform well not only in conventional CT imaging, but also in
K-edge imaging with SPCCT, supporting the feasibility of these elements for possible use
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in SPCCT imaging.18, 20, 53, 54, 57, 58 These nanoparticles can be designed to have variable
circulation times, target specificity and to deliver high payloads to regions of interest to
complement the material differentiation capability of SPCCT imaging. They are also less
likely to extravasate when compared to small molecule-based contrast agents, improving
target to background ratios in blood vessel imaging. Table 1.1 briefly summarizes the
properties (e.g., atomic number, K-edge, density) and the potential for SPCCT contrast
agent development (e.g., pro/con, development status, and degree of studies for CT and
SPCCT contrast agent) of the elements that have been most widely studied for SPCCT
imaging.
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Table 1.1 Summary of the properties and the potential for SPCCT contrast agent
development of candidate heavy metal elements.

1.2.3. Other biomedical applications of metal-based nanoparticles
1.2.3.1 CT cell tracking
CT has recently emerged as an imaging modality for cell tracking applications due
to its appealing characteristics for such applications. CT has no depth penetration limit,
has fast temporal resolution, is relatively low cost, and provides quantitative information
on contrast agents in vivo. CT cell tracking also has substantial clinical potential as CT
scanners are widely available in hospitals and research facilities. Recent developments in
CT detectors,59 reconstruction algorithms,10 and contrast agents7 have also improved the
sensitivity of CT, which has been an issue for using CT for cell tracking. The development
of cell tracking for CT is a recent technological development for the cell tracking field;
however,

numerous

studies

have

demonstrated

the

feasibility

of

tracking

microencapsulated cells, tumor cells, stem cells, and immune cells from CT imaging.
SPCCT has also been utilized for cell tracking applications as well, exploiting its unique
capability to accurately quantify exogenous contrast agent in vivo.60

1.2.3.2 ROS scavenger for immunomodulation
Nanoparticles made of certain elements, such as cerium, copper,61 manganese,62
have catalytic activities to effectively scavenge reactive oxygen species and other free
radicals. Since excessive free radicals and oxidative stress are key factors in progression
of inflammation and tissue injury, these catalytic nanoparticles have been studied to
modulate immune responses. Among the elements that can form metal oxide
17

nanoparticles, cerium has the highest atomic number (Z = 58) and K-edge energy that is
much higher than that of iodine (40.4 keV vs. 33.2 keV). Cerium’s K-edge energy is also
located in the region of high photon generation in clinical CT spectra, hinting at its potential
use in both CT and SPCCT imaging.

1.3 Conclusion
Recent advancements in both CT techniques and nanotechnology open an
opportunity to develop nanoparticle-based CT contrast agents that can overcome current
limitations of iodinated small molecule contrast agents and conventional CT systems and
improve the diagnostic qualities of CT imaging. Additional benefits from the emergence of
SPCCT, such as absolute quantification of exogenous contrast agents, and the ability to
control the physiochemical properties of nanoparticles can further broaden the CT imaging
applications beyond patient diagnoses. In the following chapters, we present the
development of various nanoparticle designs for SPCCT-specific imaging, high contrast
generation in various scanning conditions in conventional CT imaging, cell tracking and
immunomodulation.
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CHAPTER 2: ASSESSMENT OF CANDIDATE ELEMENTS FOR
DEVELOPMENT OF ULTRASMALL NANOPARTCLE-BASED PHOTONCOUNTING CT CONTRAST AGENTS
2.1 Abstract
Spectral photon-counting computed tomography (SPCCT) is a rapidly emerging
imaging modality that provides energy-dependent information of individual x-ray photons,
allowing material decomposition and simultaneous quantification of multiple contrast
generating materials. Development of SPCCT-specific contrast agents is needed to
overcome the issues with currently used iodinated contrast agents, such as difficulty in
differentiation from calcified structures, and to yield SPCCT’s full promise. In this study,
the contrast generation of several candidate elements is investigated using a prototype
SPCCT scanner based on a modified clinical CT system and suitable elements for novel
contrast agent development for SPCCT imaging are identified. Furthermore, nanoparticles
were synthesized from tantalum as a proof of concept spectral photon-counting CT agent.
In vitro cytotoxicity and contrast generation of tantalum oxide nanoparticles are tested to
provide insight into the feasibility of nanoparticle-based contrast agent development from
these elements. We found that gadolinium, ytterbium and tantalum generate high contrast
in spectral photon-counting CT imaging and may be the most suitable elements for
contrast agent development for this modality. Our proof-of-concept study results with
tantalum oxide nanoparticles underscore this conclusion due to their detectability with
spectral photon-counting CT and their biocompatibility.
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2.2 Introduction
X-ray computed tomography (CT) is one of the most widely used imaging
modalities in medicine due to its broad availability, low cost, high spatial resolution and
fast image acquisition time.1 Although it is already well-established, CT is undergoing a
period of rapid innovation. Under extensive investigation for clinical feasibility is spectral
photon-counting CT (SPCCT), an emerging form of CT that uses a standard polychromatic
x-ray source and photon-counting detectors (PCDs).2-7 Prototypes of SPCCT scanners
that have been modified from clinical CT systems are currently available for both preclinical and clinical research.2,4,5 PCDs are capable of measuring the energy levels of
individual x-ray photons unlike the energy integrating detectors (EIDs) used in
conventional CT scanners. EIDs discard the energy information of incident x-ray photons
since they sum all the energy deposited in each pixel, resulting in photons with higher
energy being weighted more heavily than photons with lower energy.8,9 PCDs achieve the
energy-resolving measurement of x-ray photons by converting x-rays into currents,
inferring their energies via pulse height analysis, and separating them into several data
bins with adjustable energy thresholds. Since different materials have differing x-ray
attenuation profiles, characterizing the energy distribution of the transmitted beam allows
specific detection of substances such as exogenous contrast agents.4,10
SPCCT systems have multiple benefits, such as improved contrast-to-noise ratios
(CNR), lower noise, higher spatial resolution and fewer image artifacts (e.g., blooming and
beam hardening).11,12 These benefits can lead to acquisition of higher quality images at
lower radiation doses than with conventional CT systems. Preclinical and clinical studies
so far have demonstrated the advantages of SPCCT imaging in several animal models,
as well as in human subjects.2,3,5,13,14 Besides the image quality and the patient dose
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advantages of SPCCT, these systems can specifically distinguish multiple contrast
generating materials in a single scan via material decomposition by assigning an
appropriate number of energy bins and their thresholds.15-20 This feature allows
differentiation of exogenous contrast agents from soft tissues and calcified structures (e.g.
bones and calcified atherosclerotic plaques), which can be especially beneficial in
coronary CT angiography. Simultaneous material decomposition also eliminates the need
for comparison of pre- and post-administration images, further reducing patient radiation
exposure. As demonstrated by Si-Mohamed et al.,4 SPCCT systems are also capable of
providing absolute quantification of exogenous contrast agents in vivo to allow
biodistribution assessment without the need for ex vivo analysis.
To date, iodine-based small molecules are the most commonly used intravenous
contrast agents for CT imaging. While contrast generation of iodinated contrast agents in
SPCCT systems is as effective as contrast generation in conventional and dual energy
CT systems, they do not take full advantage of the capability of K-edge imaging in SPCCT.
This is because there are too few photons in CT X-ray beams below iodine’s low K-edge
energy (33.2 keV) for accurate material decomposition to be completed. Iodine-based
contrast agents are also known to cause allergic reactions, and there are concerns over
kidney function reduction in patients with renal insufficiency through contrast-induced
nephropathy (CIN) or contrast-induced acute kidney injury.21,22 CIN does not develop into
chronic renal failure in most cases; however, it may still result in complete renal failure in
the patients with poor renal function, increasing the risk of morbidity and mortality.23 Thus,
developing novel contrast agents specifically designed for SPCCT systems can be
valuable to allow full utilization of its capabilities and broaden its applications. Substantial
work has been done over the past decade using nanoparticles made of heavy metal
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elements, such as gold,24-28 bismuth,29,30 tantalum31,32 and others33-37, as contrast agents
for EID-based CT. These nanoparticle-based CT contrast agents can be synthesized to
have similar or different pharmacokinetics and biodistributions to iodine. They have been
studied for various applications, such as vascular imaging,25,38 theranostics in drug
delivery39 and radiotherapy,40 as well as cell tracking.41,42 For effective imaging, contrast
agents for SPCCT imaging need to be based on elements that have K-edge energies
within a region where there are a reasonable number of photons both above and below
their K-edge energy (roughly 40–100 keV in a 120 kVp beam) (Figure 2.1). There have
been a number of reports that focus on the use of contrast agents made of heavy metal
elements (e.g., gold, bismuth or gadolinium) for SPCCT imaging.10,17,18,43 However, there
is a lack of systematic studies that examine contrast generation from different elements in
SPCCT imaging.
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Figure 2.1 Candidate heavy metal elements for SPCCT contrast agent development.
(A) Mass attenuation coefficients of various heavy metal elements and X-ray photon
intensities at a tube voltage of 120 kV. The X-ray photon intensity spectrum (dotted line)
was generated by using Spektr 3.0 (x-ray spectrum modeling software). (B)
Characteristics of the six heavy elements used in this study. The salt prices of these
elements were obtained from Sigma-Aldrich.

We therefore decided to survey various heavy metal elements for candidates for
novel SPCCT contrast agents. From elements whose K-edge fell into the range of 40–
100 keV, we first eliminated those that are highly toxic or radioactive, such as thulium and
32

radium.12 Then we considered economically viable elements that have been previously
studied as experimental contrast agents or for nanoparticle synthesis. Taking these criteria
into consideration, we selected gadolinium, ytterbium, tantalum, tungsten, gold and
bismuth as the most suitable elements for contrast agent development (Figure 2.1B). Gold
has been most extensively studied as a contrast generating material for SPCCT,4,17,44
therefore we included it in this panel despite its relatively high material cost. We herein
report the contrast production of these elements using a prototype SPCCT system with a
high-count rate that can cope with photon fluxes needed for medical imaging.
Nanoparticle-based contrast agents from a lead element can allow successful
material differentiation from calcified structures to broaden the applications of SPCCT
imaging.45

These

nanoparticles

can

also be

synthesized to

have

favorable

pharmacokinetics and biodistribution and to act as a platform for targeted imaging, further
expanding the potential role of SPCCT imaging. Therefore, we formed nanoparticles with
a lead element and performed a series of proof-of-concept experiments to provide insight
into the feasibility of SPCCT contrast agent development from these candidate elements.
By identifying elements that produce high CNR in a prototype SPCCT scanner, this study
provides guidance for the future development of novel SPCCT-specific contrast agents.

2.3 Materials and methods
2.3.1 Materials
Gadolinium(III) acetate hydrate (99.9% trace metals basis), ytterbium(III) chloride
hexahydrate (99.9%), tantalum(V) chloride (99.8%), tungsten(VI) chloride (99.9%),
gold(III) chloride trihydrate (99.9%), bismuth(III) nitrate pentahydrate (98.0%), tantalum(V)
ethoxide (99.98%), cyclohexane (99%), IGEPAL CO-520, ammonium hydroxide solution
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(28.0–30.0% NH3 basis) and calcium phosphate (96.0%) were purchased from SigmaAldrich

(St.

Louis,

MO).

2-(carbomethoxy)ethyltrimethoxysilane

and

3-

(trimethoxysilyl)propyl-N,N,N-trimethylammonium chloride were obtained from Gelest, Inc
(Morrisville, PA). Iomeron 400 mg/ml was purchased from Bracco (Milan, Italy). The cell
lines used for in vitro experiments (i.e., HepG2, Renca, SVEC4-10EHR1) were provided
by ATCC (Manassas, VA). LIVE/DEAD assay kits were purchased from Life Technologies
Invitrogen (Grand Island, NY).

2.3.2 CT and SPCCT systems
A prototype SPCCT scanner (Philips Healthcare, Haifa, Israel) modified from a
clinical CT system, located at the University of Lyon, was used to acquire phantom images.
As previously described,4 the scanner has field-of-view (FOV) of 168 mm in-plane, zcoverage of 2 mm, gantry rotation time of 0.75 seconds (2400 projection per rotation), focal
spot of 0.7 × 0.7 mm, isotropic pixel size of 250 µm, and in-plane resolutions of 11.4 lp/com
(line pair per cm) at 50% modulation transfer function (MTF) and 22.4 lp/cm at 10% MTF.16
The scanner is equipped with a PCD made of high band gap semiconductor cadmium zinc
telluride with a pixel pitch of 500 × 500 µm (Figure 2.2).46

Figure 2.2 Specifications and photograph of the prototype SPCCT scanner used in this
study.
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The energy-resolving detector has 5 configurable energy thresholds. The
phantoms were scanned using 5 energy bins whose thresholds were set specifically for
each candidate element in this study to allow K-edge imaging (e.g. 30, 51, 78, 83 and
98 keV for gold). For each element, two energy bin thresholds were set just below and
above its K-edge for optimal signal-to-noise ratio and higher accuracy in quantitative
information of the element, as described by Roessl et al.47,48 Five axial scans were
performed using a conventional x-ray tube with a peak voltage of 120 kVp and current of
100 mA. A Philips Ingenuity CT (Philips Healthcare, Cleveland, US), a conventional clinical
CT located at the University of Lyon, was also used to acquire phantom images for CT
attenuation analysis. The images were acquired using FOV of 500 mm, 160 mm
reconstruction diameter, slice thickness of 1 mm, pixel spacing of 0.3125 mm and gantry
rotation time of 0.4 seconds in full 360° scans. The same scan parameters (i.e. tube
voltage of 120 kVp and current of 100 mA) were used to acquire the phantom images with
both scanners, which are of the same geometry.

2.3.3 SPCCT phantom imaging and image analysis
A polyoxymethylene cylindrical phantom body that is 13 cm in diameter and with
twelve holes for tube insertions was used as the phantom (Figure 2.3). A range of
concentrations of each element (i.e. 0, 0.5, 1, 2, 4, 6, 8, and 12 mg/ml) in either ethylene
glycol for bismuth nitrate or in deionized water for all other precursor salts (i.e., gadolinium
acetate, ytterbium chloride, tungsten chloride and gold chloride) were placed in the outer
eight holes. Ethylene glycol was used to dissolve bismuth nitrate since it is poorly soluble
in water.49 Two vials containing either 2 mg/ml or 5 mg/ml of iodinated media (Iomeron),
one vial containing a bone simulant (calcium phosphate solution) and one empty vial (for
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air measurement) were placed in the inner four holes. All solutions were prepared in 1.5 ml
polypropylene centrifuge tubes (Eppendorf, Hauppauge, NY).

Figure 2.3 SPCCT phantom design and images.
(A) Schematic depiction of sample tube locations on the phantom and the energy bin
thresholds used for each element. (B) Four images generated from SPCCT imaging.
Images of gadolinium are shown as an example.

For image analysis, we assessed attenuation rate (AR) and CNR rate (CNRR). AR
was defined as attenuation divided by the concentration of the elements in mg/ml. CNRR
was defined as CNR divided by the concentration of the element. CNR was calculated by
subtracting the signal in water from the signal from a sample, then dividing the resulting
number by the noise. Noise from the images for each element was determined by
measuring the standard deviation in water tube using OsiriX v.3.7.1 64-bit software
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(Pixmeo SARL, Bernex, Switzerland). Circular regions of interest (diameter 6.5 mm, area
33.18 mm2) were drawn in the middle of each sample tube, and the output from each ROI
was recorded. Conventional CT equivalent images were used to calculate AR and element
specific K-edge images were used for CNRR. To measure AR, the attenuation values from
conventional CT equivalent images (as attenuation on y axis) were graphed against mass
concentration of the elements (mg/ml on x axis), and the slope of the linear line of best fit
was calculated.26 Similarly, the CNR values from element-specific K-edge images were
compared against element concentrations to determine the CNRR. Every ROI
measurement was performed on slice thickness of 2 mm.

2.3.4 Material decomposition and image reconstruction method
Each slice was reconstructed into conventional CT equivalent images, element
specific images, water images, and iodine images (see Figure 2.3B for example). Using
the energy information of the transmitted photons in all five energy bins, conventional CTequivalent images were synthesized, in which the data is displayed in Hounsfield units.
Specifically, these images are generated by best fit of the measured count rates in all five
energy bins to calibration data, based on the phantom with various path lengths. A
maximum-likelihood material decomposition based on literature data on the CT
attenuations of the target materials was applied to derive three material sinograms –
element-specific, iodine and water – from the distribution of photon counts across the five
energy bins.
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2.3.5 Tantalum oxide nanoparticle synthesis
Sub 5-nm tantalum oxide nanoparticles (TaONP) were synthesized by modifying
the microemulsion method described by Oh et al.31 Microemulsions were prepared by
adding 250 uL of 75 mM NaOH solution to 20 mL of cyclohexane containing 2.7 g of
IGEPAL CO-520. 50 uL of 0.3 mM tantalum(V) ethoxide solution (78.3 mg), as provided
by the supplier, was added to this emulsion. The resulting mixture was incubated for
15 min

while

stirring.

To

make

TaONP

water-soluble,

70 uL

of

2-

(carbomethoxy)ethyltrimethoxysilane and 200 uL of 3-(trimethoxysilyl)propyl-N,N,Ntrimethylammonium chloride in 1 ml of ethanol were added to the nanoparticle solution.
After 24 hr of stirring at room temperature, a white sediment had formed at the bottom of
the flask. The colorless supernatant was removed via careful aspiration, and the white
sediment was dissolved in 5 mL of 5 M ammonium hydroxide solution and allowed to stir
for 30 min. At which point, 25 ml of ultrapure water was added, and the resulting solution
was centrifuged at 2500 g for 15 min. This centrifugation step resulted in separation of the
aqueous phase from remaining cyclohexane and aggregates, which formed a pellet. The
clear aqueous solution was collected by careful pipetting, leaving behind the aggregates
and cyclohexane. The resulting nanoparticle solution was further purified and
concentrated by centrifugation and washing in deionized water three times using 10 kDa
MWCO centrifugation tubes (GE Healthcare Life Sciences, Marlborough, MA). Each batch
of solution was then redispersed in 4 ml of PBS, centrifuged at 5000 g for 10 minutes in
1.5 mL centrifuge vials, and was filtered through 0.22 μm syringe filter. The final
nanoparticle solution was stable in both deionized water and PBS.
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2.3.6 Nanoparticle characterization
Transmission electron microscopy (TEM) was used to evaluate the morphology
and core size of TaONP. The microscope used was a JEOL 1010 (JEOL USA Inc.,
Peabody, MA). ImageJ was used to determine the average diameter of nanoparticle cores
from the electron micrographs. The hydrodynamic diameter and ζ-potential of TaONP
were determined using a Nano ZS-90 Zetasizer (Malvern Instruments, Worcestershire,
UK). The concentration of TaONP was determined via inductively coupled plasma atomic
emission spectroscopy (ICP-OES). To prepare ICP samples, 5–10 μL of nanoparticle
solution was dissolved in 1 mL of aqua regia (one part nitric acid to three parts hydrochloric
acid) for 3 hr before adding ultrapure water to make the final volume to 5 mL. The resulting
solutions were analyzed with a Spectro-Genesis ICP (Spectro Analytical Instruments
GmbH, Kleve, Germany) for tantalum concentration.

2.3.7 In vitro cytotoxicity experiment
The LIVE/DEAD assay (Life Technologies, Frederick, MD) was used to study the
effect of TaONP on the viability of Renca (epithelial kidney cells), SVEC4-10EHR1
(endothelial cells), and HepG2 (hepatocytes). The cells were cultured in 20 mm glass
bottom dishes at a seeding density of 1.0 × 105 per dish for 24 hr at 37 °C and 5% CO2.
The cell growth medium recommended by ATCC for each cell line was used. Next, the
media was removed and replaced with fresh media containing various concentrations
(0.025 mg/ml to 1 mg Ta/ml) of TaONP. After 8 hr incubation with TaONP, cells were
washed twice with DPBS and treated with 400 μL of LIVE-DEAD cocktail (2 μL of ethidium
homodimer-1, 1 μL calcein AM, and 3 μL of 3.2 mM Hoechst 33342 in 2 mL DPBS) for
20 min. The cells were then imaged with a Nikon Eclipse Ti-U fluorescence microscope to
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visualize cell nuclei, living cells and dead cells. Images from four different fields of view in
each dish were acquired. The images were analyzed by a custom-made MATLAB code
to count the number of cells. The cell viability percent was calculated by dividing the live
cell count by total number of cells. These experiments were repeated three times for each
cell line.

2.3.8 Statistical analysis
The LINEST function of Excel was used to determine the slope (𝑚χ ) and standard
error of fit (𝑒χ ) of both AR and CNRR. Following the calculation of 𝑚χ and 𝑒χ , the following
equation was used to calculate t-values:
𝑡1−2 = (𝑚1 − 𝑚2 )/√(𝑒12 + 𝑒22 )
The t-values were then compared with the 5% reference t-value at degrees of freedom of
12 (7 concentration points from 1st element (n1) + 7 concentration points from 2nd element
(n2) – 2), which is 2.18. Comparisons were made between every possible pair of the six
elements used in this study. Linear regression and Bland-Altman analyses were
performed to assess correlation between AR obtained from the conventional CT and the
SPCCT system. One-way analysis of variance (ANOVA) and Tukey-Kramer HSD
(honestly significant difference) posthoc test was used for in vitro cytotoxicity experiment.

2.4 Results
2.4.1 Phantom imaging
Conventional CT equivalent, element specific, iodine, and water images were
successfully generated from scanning the phantom (Figure 2.3B). An increase in
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attenuation can be observed as element concentration increases in the conventional CT
equivalent image. Element-specific images demonstrated that each K-edge element could
be successfully differentiated from other materials in the field of view, including calcium
phosphate, iodine and the phantom body.

2.4.2 Attenuation rate
There was an excellent linear correlation between the attenuation observed in
conventional CT equivalent images and element concentration, as is typically the
case.4,17,26 The data for gadolinium is displayed in Figure 2.4A as an example. All six
elements had an R2 value very close to unity (Table 2.1). We found that gadolinium had
the highest value of AR, followed by tantalum, ytterbium, gold, tungsten and bismuth
(Figure 2.4B). We also observed that there was a noticeable decrease in AR value
between atomic number 73 (tantalum) and 74 (tungsten). The differences between most
of the pairs of elements were statistically significant, except for gadolinium and tantalum,
tungsten and bismuth, tungsten and gold, and gold and bismuth (Table 2.2A). It appears
that within the section of the periodic table studied and this scanner, high Z-elements
whose atomic number is equal to or less than 73 generate about 20% more attenuation
compared to elements whose atomic number is higher than 73, on average.

Figure 2.4 Attenuation rates of candidate elements from SPCCT system.
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(A) Attenuation of gadolinium at a range of concentrations. (B) Attenuation rates of
different elements studied. Error bars represent the standard error of the regression. For
data points where the error bars are not visible, this is because the error value is very low
and is obscured by the data point.

Table 2.1 R2 value of AR in all six elements in the phantom study.

Table 2.2 T-values of every possible pair of elements in two sample T-test for AR.
A) conventional CT equivalent images from SPCCT and B) images from conventional CT.
The pairs that did not have statistically significant differences in AR are highlighted in gray.
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To examine whether this observed trend from a SPCCT system was also present
in data acquired from EID-based CT images, the phantom was also imaged with a
conventional CT scanner with the same tube current and voltage. As can be seen in Figure
2.5A, the AR values of the elements from conventional CT images were fairly similar to
that of the elements from SPCCT images, ranging from 25.2 to 33.0 HU·ml·mg −1 (as
opposed to 26.0 to 33.1 HU·ml·mg−1 in CT equivalent images from SPCCT). The
differences in AR between the elements were less noticeable in conventional CT images,
and the decrease in AR between tantalum and tungsten was less apparent. In fact, there
was no statistical differences between gold and four different elements (gadolinium,
ytterbium, tantalum, tungsten), tantalum and two elements (gadolinium and ytterbium),
and tungsten and two elements (gadolinium and tantalum) (Table 2.2B).

Figure 2.5 Comparison in AR between CT and SPCCT systems.
(A) The attenuation rates of different elements studied in conventional CT. (B) BlandAltman analysis of attenuation rate from CT and SPCCT systems. The same key for the
elements is used in both A and B.

Bland-Altman analysis was also used to demonstrate the agreement of two AR
values between SPCCT and CT. As seen in Figure 2.5B, the mean of differences, as
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known as bias, was 0.27 HU·ml·mg−1 with limits of agreement at −5.1 HU·ml·mg−1 and
5.6 HU·ml·mg−1. The differences in AR values for all elements in the study were below the
limit of agreement and were distributed in a small range near the bias with the highest
difference observed in gadolinium (difference of 4.3 HU·ml·mg−1). This shows that AR
values derived from SPCCT images are comparable to those from conventional CT
images.

2.4.3 Contrast-to-noise ratio rate and noise
As can be seen in Figure 2.6A, the CNR values from element-specific images were
linearly correlated with element concentration. Similar to AR, CNRR of all six elements
had R2 values very close to unity (Table 2.3), demonstrating the capability of this SPCCT
system to accurately quantify the concentrations of the elements, similar to results found
for gold in previous studies.4,17

Figure 2.6 CNR rates of candidate elements from SPCCT system.
44

(A) CNR of gadolinium at a range of concentrations. (B) CNRR of the different elements
studied. (C) CNRR of the different elements compared with their K-edge energies. (D)
CNRR of the elements compared to the ratio of number of photons above and below their
K-edge energies (based on the photon spectrum in the air shown in Figure 2.1A). The
same key is used for B-D. CNR and CNRR were calculated from the element specific
images.

Table 2.3 R2 value of CNRR in all six elements in the phantom study.

45

Table 2.4 T-values of every possible pairs of elements in two sample T-test for CNRR in
element specific images of SPCCT. The pairs that did not have statistically significant
differences in CNRR are highlighted in gray.

CNRR values were the highest for ytterbium, followed by tantalum, gadolinium,
tungsten, gold and bismuth (Figure 2.6B). There were no statistically significant
differences in CNRR values between gold and bismuth as well as gold and tungsten, but
the CNRR values were found to be statistically significantly different between all other
possible pairs of elements (Table 2.4). The differences were also substantial, with the
CNRR for ytterbium being 62% and 58% higher than those for bismuth and gold,
respectively. Similar to AR, CNRR was lower for elements whose atomic number was 74
or above, compared with elements 73 or lower. This created two groups of elements, one
that has high CNRR (gadolinium, ytterbium, tantalum) and the other with low CNRR
(tungsten, gold, bismuth). In an effort to understand the variation in CNRR, we examined
its relationships with other parameters, such as the K-edge energy of the elements and
the ratio of number of photons above and below the K-edge energy. As can be seen in
Figure 2.6C, the elements whose K-edge energies are at 67.4 keV (tantalum) or below
have higher CNRR than the elements whose K-edge energies are at 69.5 keV (tungsten)
or above. Since having sufficient numbers of photons both below and above the K-edge
energy is considered to be an important factor in ideal reconstruction of element specific
images, we also analyzed CNRR in terms of the photon flux ratio above and below the Kedge energies. We observed that higher photon flux ratios closer to one resulted in higher
CNRR values (Figure 2.6D). Last, we examined the noise in the element specific images
(Figure 2.7). Noise was the main determinant of CNRR in SPCCT imaging. Low noise was
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observed for the elements whose atomic numbers are less than or equal to 73, while
higher noise was observed in elements whose atomic numbers are higher than 73 (Figure
2.7A). We also observed that noise level generally decreases with increasing photon flux
ratio above and below the K-edge energies (Figure 2.7B).

Figure 2.7 Noise level of candidate elements.
(A) Noise levels of the element specific images. (B) Noise level from the element specific
images compared to the ratio of numbers of photons above and below the K-edge energy
for each element.

2.4.4 Tantalum oxide nanoparticle synthesis and characterization
As demonstrated in the phantom imaging, tantalum had one of the highest AR
values along with gadolinium and the second highest CNRR value after that of ytterbium.
Moreover, its high elemental density (d = 16.4 g/cm3), affordability (approximately 13-fold
cheaper than gold and 4-fold cheaper than ytterbium) and suitable K-edge energy (67.4
keV) that can lead to material differentiation from calcified structures in SPCCT make
tantalum an appealing element for further development into a SPCCT contrast agent. To
test the potential use of tantalum-based contrast agents in SPCCT imaging, water-soluble,
sub-5 nm TaONP were synthesized. TaONP were synthesized using a microemulsion
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method and were given a zwitterionic small molecule coating to provide solubility and
stability in biological media (Figure 2.8A).50 The size and surface potential of TaONP were
characterized by TEM and DLS (Figure 2.8B). The mean core diameter measured from
TEM images was 4.9 nm. The mean hydrodynamic diameter of 12.5 nm was slightly larger
than the core diameter as expected, due to the molecules attached to the nanoparticle
surface. The surface potential of TaONP was found to be slightly negative
(−11.1 ± 2.1 mV).

Figure 2.8 Synthesis and physiochemical characteristics of TaONP.
(A) Schematic depiction of the TaONP synthesis process. (B) TEM of TaONP, size and
surface potential of TaONP measured from TEM and DLS.

2.4.5 In vitro cytocompatibility of tantalum oxide nanoparticles
To study the safety of TaONP, they were incubated with cell types that are
expected to have high exposure upon administration, i.e. hepatocytes, endothelial cells
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and epithelial kidney cells (Figure 2.9). There was no statistically significant effect on cell
viability from TaONP treatment for any cell type or treatment concentration, which
indicates the safety and potential use of TaONP for biomedical applications.

Figure 2.9 Effect of TaONP on cell viability after 8 hr of incubation.

2.4.6 SPCCT phantom imaging of tantalum oxide nanoparticles
To study the capabilities of the SPCCT system in differentiating TaONP from other
elements (i.e. iodine) and the detection limit of TaONP, phantom images of TaONP were
acquired. As seen in Figure 2.10, the scanner could accurately determine the location of
TaONP in the field of view. Iodine and calcium phosphate were clearly distinguished from
TaONP. TaONP-specific images indicate that concentration as low as 1 mg/ml of TaONP
can be detected in the SPCCT scanner, which is comparable to the detection limit of gold
at 1 mg/ml in conventional CT scanner.26
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Figure 2.10 SPCCT imaging of TaONP.
SPCCT images of the phantom showing differentiation of TaONP ranging from 0 to 12 mg
Ta/ml from an iodine-based contrast agent (2 and 5 mg/ml). Two images on the bottom
row are the enlarged iodine and TaONP images centered at tubes with lower element
concentrations.

2.5 Discussion
We have demonstrated that gadolinium, ytterbium and tantalum provide higher CT
signal generation and better element-specific CNR over tungsten, gold and bismuth in the
current prototype SPCCT system used in this study. These results suggest that the
elements in the range of atomic numbers between 64 to 73 can be suitable candidates for
future development into high-performing contrast agents for SPCCT imaging. Despite the
similarity in atomic number, tungsten (Z=74) had significantly lower attenuation. This is
possibly due to the fact that tungsten is the material of the x-ray tube anode, which causes
K-edge absorption within the tube at the K-edge energy of tungsten. Besides gadolinium,
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ytterbium, and tantalum, other elements whose atomic numbers are close to them (e.g.
cerium, europium, terbium, hafnium) can also potentially generate the most contrast in
SPCCT. Cerium and hafnium could particularly be interesting to study their feasibility as
SPCCT contrast agents since their nanoparticle forms have been well-studied for other
biomedical applications.51-53
High attenuation and CNR observed from gadolinium, ytterbium and tantalum can
be explained by the fact that their K-edge energies are located where there are high
photon numbers both above and below the energies in a 120 kVp beam. This helps to
acquire better data statistics for more accurate material decomposition and hence lower
image noise. These findings in our study were demonstrated at a scanning condition of
120 kVp peak tube voltage. It is important to note that gold and bismuth – two elements
that generated less contrast in this study – will likely produce stronger contrast at 140 kVp
since more photons will be generated near (especially above) their K-edge energies.
Several studies have examined nanoparticle development and small animal imaging with
ytterbium54-56 and tantalum,31,32,57 indicating the potential of these two elements for further
development for SPCCT contrast agents. However, more research is needed to evaluate
nanoparticle behaviors, such as long-term in vivo cytotoxicity, biodistribution and optimal
dosage before we can start clinical translation. Ease of size control and surface coating
can make tantalum a more desirable element for nanoparticle-based contrast agent
development than ytterbium.
For phantom images provided in Figure 2.3, iodine and water images were
constructed in a similar manner as dual energy CT images in which all materials are
mapped; therefore, materials other than water and iodine are also seen in these images.
Since the element samples were dissolved in water or a water-like solvent (i.e. ethylene
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glycol in the case of bismuth), there is some signal from these samples in the water image
as well (Figure 2.3B). Similarly, the plastic of the phantom also appears on the water
images due to the fact that it is composed of elements similar to the atomic numbers of
hydrogen and oxygen. This also explains the slightly larger appearance of the samples in
water images since the plastic tubes containing the samples also appear. In all cases,
signal from calcium phosphate is seen in both iodine and water images with higher
attenuation than other elements since the material decomposition algorithm classifies the
attenuation pattern of calcium to be in between that of iodine and water. This agrees with
observations made in previous studies using SPCCT.4,17
Optimization of energy windows is an important issue for K-edge imaging since the
energy thresholds of each energy bin greatly affect the material decomposition as well as
CNR of the materials in SPCCT imaging. The selection of energy bins determines the
spectral separation and the count rate of each energy bin as well; thus, they have to be
optimized for given set of materials. For K-edge of an element to be detected, the energy
bins must properly capture the K-edge. This is typically done by assigning the energy
thresholds of a bin just below and above the K-edge energy. Before our study, energy
thresholds for all five energy bins were optimized for each element used in this study,
based on the methods described by Roessl et al. The optimization focused on minimizing
the noise in material decomposition and improving the signal-to-noise ratio in materialspecific images of each element.47,48 For example, energy thresholds of 30, 51, 78, 83,
and 98 keV were used for gold whose K-edge energy is 80.7 keV.
Besides the energy bin thresholds, different types of material decomposition
algorithms can also lead to different degrees of signal-to-noise ratio degradation and
variances in noise. In this study, we performed projection space-based material
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decomposition. However, decomposition can be performed on reconstructed images,
which can yield different noise levels.58 Recently, one-step inversion algorithms called
statistical iterative reconstruction techniques that can improve image quality has been
investigated by Mechlem et al.59 The continued improvement in material decomposition
techniques can lead to decreased noise levels in material-specific images of all six
elements in this study.
The proof-of-concept experiments with tantalum-based nanoparticles confirmed
that, as others have found, biocompatible nanoparticles can be made with this
element.31,60 In addition, we showed for the first time that these nanoparticles can be
successfully differentiated from calcium phosphate and iodine with SPCCT. The detection
limit of TaONP was also comparable to that of gold in conventional CT systems
(approxiamtely

1 mg/ml).

By

using

improved

image

reconstruction

methods,

reconstruction kernels and post-image processing (i.e. removal of ring artifacts and
Gaussian blurring), it is expected that the detection limit of TaONP, as well as other
elements, will continue to be improved.61 Along with other nanoparticle-based contrast
agents, TaONP have further advantages over iodinated contrast agents as blood pool
agents in SPCCT imaging, since their biodistribution and pharmacokinetics can be
controlled by adjusting the size and surface chemistry to lessen renal damage and
optimize the imaging window.62
As demonstrated in this study, gadolinium, ytterbium, and tantalum can be
particularly valuable elements for further developments into SPCCT contrast agents,
considering their low toxicity, cost, availability, and previous uses in nanoparticle synthesis
and developmental contrast agents. We also showed that these elements could work well
in conventional CT scanners, which can provide additional utility of the contrast agents
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made of these elements. Gadolinium-based contrast agents are commercially available
and are widely used for clinical uses in MR imaging.63 However, due to lower sensitivity in
CT scanners, higher doses of gadolinium will likely be needed for SPCCT imaging, which
may result in toxicity issues. Indeed, there is considerable concern over brain retention of
gadolinium-based agents.64 While the concern may hinder immediate use of gadolinium
for SPCCT imaging, the possibility of eventual usage remains high. A recent study
demonstrated the feasibility of acquiring images of diagnostic quality with gadoliniumbased contrast agents at clinical MRI routine doses of 0.2 mmol/kg in human patients via
spectral CT imaging.65 The required doses of gadolinium-based contrast agents for in
vivo imaging are expected to be reduced with improving sensitivity of SPCCT
technology.61 Nevertheless, further work is needed to fully understand the potential use of
the currently available gadolinium-based agents for SPCCT imaging.
Although contrast generation is a valuable assessment of an element’s potential
SPCCT imaging performance, it is one of several factors that need to be considered for
CT imaging applications. For instance, in the case of cell tracking, there is a need for high
contrast agent density to allow cells to take up high payloads while having good
biocompatibility and stability. To date, gold nanoparticles have almost exclusively been
used for cell tracking with CT1 since they meet all of the above criteria. Therefore, gold
nanoparticles may remain the platform of choice for cell tracking with SPCCT, despite the
sub-optimal CNR. Inferior CNR of gold found in this study is likely due to the fact that we
were using tube voltage of 120 kVp. As mentioned earlier in the discussion, gold is likely
to provide better contrast at 140 kVp.26 Furthermore, gold nanoparticles have been
frequently used as experimental CT contrast agents in general due in part to the ability to
synthesize them in a wide variety of sizes and shapes, as well as the ability to conjugate
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them with targeting ligands. These are much easier to accomplish than other elements
such as tantalum.66-68 We may therefore continue to see reports of gold nanoparticle
SPCCT agents.
Our study provides insight into potential elements that can be developed as
contrast agents for SPCCT imaging, but it has limitations. Similar studies will need to be
performed in other SPCCT systems to further validate the potential elements for SPCCT
contrast agents as variations in system specifications may result in different trends in CT
attenuation and CNR. Moreover, the SPCCT system used in this study is a prototype of a
clinical scanner under development. The final clinical scanner may have a different x-ray
source, detector architecture and may use different scanning conditions, which could
result in some differences with the values reported herein. Scanning in a larger FOV for
larger subjects, such as human patients, may affect CNR production via the beam
hardening effect, causing fewer photons below the K-edge energies of these elements to
reach the detector. In this case, elements with higher atomic numbers will therefore
produce higher CNR than for smaller subjects. This might lead to, for example, the contrast
generation of tantalum being higher than that of ytterbium. All of these limitations of the
study can be addressed in the future in larger phantoms or animal models as the
technology approaches the clinical stage of the development.

2.6 Conclusion
In summary, the results from this study suggest that gadolinium, ytterbium and
tantalum can generate high attenuation and contrast-to-noise ratio in SPCCT, indicating
that these elements may be superior candidates for further development into novel
contrast agents for SPCCT imaging. Our data also suggests that these elements can
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potentially be effective as contrast generating media for conventional CT scanners. Lastly,
we have shown that tantalum can be developed into nanoparticles that are stable and
biocompatible for biological applications. These nanoparticles could be differentiated from
water, iodine and calcium phosphate in SPCCT, providing potential applications in the
field of cardiovascular and cancer imaging.
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CHAPTER 3: DEVELOPMENT OF POLYMER-ENCAPSULATED
“POLYMETAL” NANOPARTICLES FOR CT IMAGING
3.1 Abstract
Numerous formulations of nanoparticle-based X-ray computed tomography (CT)
contrast agents made of heavy metal elements are under investigation for their ability to
provide improved CT imaging. Most of these experimental nanoparticle-based CT contrast
agents have been developed with atoms of a single element thus far. However, inspired
by the composites formed from multiple elements used in radioprotective garments, we
hypothesized that contrast agents made of several elements whose K-edge energies are
spaced out in the high photon flux region could achieve high, broadband X-ray attenuation
for different energy spectra used in clinical setting. Herein, we synthesized sub-5 nm core
inorganic nanoparticles made of gold, tantalum, and cerium, and encapsulated them in
polymeric nanoparticles to form polymetal nanoparticles (PMNP). We found that PMNP
with multiple payload elements generate higher and more stable CT contrast than contrast
agents made from a single contrast generating material, demonstrating the potential
benefits of incorporating multiple suitable elements as CT contrast payloads.
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3.2 Introduction
As the field of nanomedicine has advanced, a myriad of nanoparticle formulations
has been developed for imaging applications. Nanoparticle-based contrast agents for Xray computed tomography (CT) imaging are no exception to this substantial research
interest.1-7 This interest stems from the numerous advantages of CT, such as high spatial
and temporal resolution, fast acquisition time, no depth limit, and wide clinical availability.
These inherent properties of CT have allowed it to become one of the most valuable
instruments for cardiovascular imaging. However, current FDA-approved CT contrast
agents for intravenous administration (i.e., iodinated small molecules) have several
drawbacks. These drawbacks include injection of high doses, short imaging window and
possibility of allergic reactions and renal toxicity, which are mostly caused by short blood
circulation times of small molecules.8-10 The concern over contrast-induced nephropathy
is particularly serious in patients with renal insufficiency. Since patients with vascular
diseases (who undergo frequent CT imaging for diagnoses) often have comorbid renal
diseases,11 there is a need to develop alternative CT blood pool contrast agents.
Despite the need, no new CT contrast agent has been approved for clinical use in
nearly three decades;12 however, this might soon change as numerous sizes, shapes, and
structures of experimental CT contrast agents have been recently reported,
complementing the rapid progression of CT technology in detectors and image
reconstruction methods.1,6,13 Most of these reports have focused on nanoparticles formed
from dense, heavy metal elements, such as gadolinium, ytterbium, tantalum, gold, and
bismuth.14-19 Among nanoparticles made of these elements, gold nanoparticles (AuNP)
are by far the most well-studied CT contrast agents due to their favorable characteristics.
These characteristics include high elemental density (d = 19.3 g/cm3), excellent
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biocompatibility, and ease of control over its size, morphology, and surface
chemistry.20,21 However, gold is a relatively expensive material whose use could
potentially increase the cost of CT imaging. Another heavy metal element that has been
studied is tantalum.4,16,22,23 Tantalum is also an appealing element for contrast agent
development because of its high density (d = 16.4 g/cm3) and its K-edge energy (67.4
keV), which is located in a high photon flux region.24 Moreover, a recent study from Kim
et al. identified tantalum as one of the most viable elements for nanoparticle contrast agent
development for CT imaging by demonstrating tantalum’s high CT contrast production as
compared to other candidate elements.23 Many other candidate elements exist that may
be suitable to be used as novel CT contrast agents. An element with high potential, but
has rarely been investigated for CT imaging, is cerium. Cerium also has its K-edge energy
(40.4 keV) located in a high X-ray photon flux region, and cerium-based nanoparticles
have been well-studied for numerous biomedical applications using their antioxidant
activities and ROS scavenging abilities.25-27
Radioprotective garments worn by interventional radiologists are commonly known
as lead clothing; however, they frequently contain a minority of lead, or no lead at all. This
is because it is more effective in X-ray attenuation and lighter in weight to use composites
of elements, such as tungsten, tin, barium, antimony, and bismuth, whose K-edges are
spread through the range of energies used in medical imaging.28,29 Inspired by such
composites in radioprotective garments, we hypothesized that a contrast agent that
incorporates multiple elements whose K-edges are spread over the diagnostic X-ray
energy range might prove to have high contrast generation. The K-edge energies of the
elements noted above (gold = 80.7 keV, tantalum = 67.4 keV, cerium = 40.4 keV) span
the high photon flux regions of the X-ray spectra in the diagnostic range of tube voltage
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settings for μCT imaging (Figure 3.1A) and clinical CT imaging (Figure 3.1B). Moreover,
tantalum and cerium are cheaper than some of the leading elements for CT contrast agent
development, such as gold and platinum.23 Thus, polymetal nanoparticles (PMNP) can
potentially be lower in cost.

Figure 3.1 Contrast generating materials and structure of PMNP.
Mass attenuation coefficient of cerium, tantalum, and gold and estimated X-ray photon
spectra of (A) a MILabs μCT scanner at 50 kVp tube voltage and (B) a SOMATOM Force
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clinical CT scanner at 80, 100, 120, and 140 kVp. (C) Schematic depiction of PMNP
formation and breakdown.

Our PMNP formulation is designed to encapsulate small gold, tantalum, and
cerium nanoparticles that are sub-5 nm in core diameter in a larger polymer-based
nanoparticle made of biodegradable poly-di(carboxylatophenoxy)phosphazene (PCPP)
(Figure 3.1C). PCPP belongs in a family of polymers known as polyphosphazenes, whose
chemistry is defined by its phosphorus–nitrogen backbone. These polymers are wellstudied for numerous biomedical applications, such as adjuvants for immunization and
drug carriers, due to their excellent biocompatibility, tunability, and hydrophilicity. 3032

These polymers are suitable for encapsulating small nanoparticles with hydrophilic

coatings due to their hydrophilicity. They also slowly degrade into harmless hydrophilic
byproducts, such as phosphate, tyrosine, ammonia, and 4-hydroxybenzoic acid, allowing
PCPP-based nanoparticles to remain intact for several hours before degradation.33 Our
findings in this study suggest that our PMNP formulation can successfully encapsulate
small sub-5 nm core inorganic nanoparticles made from gold, tantalum, and cerium. We
have also shown that these PMNP are cytocompatible and biodegradable with robust CT
contrast properties.

3.3 Materials and methods
3.3.1 Materials
Gold(III) chloride trihydrate (>99.9% trace metals basis), tantalum(V) ethoxide
(99.98%), cerium(III) nitrate hexahydrate (99.99%), L-glutathione reduced, poly(acrylic
acid), cyclohexane, IGEPAL CO-520, ammonium hydroxide solution (28.0–30.0%
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NH3 basis),

sodium

hydroxide

concentration

(0.1

N),

poly(bis(4-

carboxyphenoxy)phosphazene) disodium salt (PCPP, 1 MDa), sodium borohydride,
spermine tetrahydrochloride, and calcium chloride dihydrate were purchased from SigmaAldrich (St. Louis, MO). Herringbone microfluidic chip mixers were obtained from
Microfluidic ChipShop (Jena, Germany). 2-(Carbomethoxy)ethyltrimethoxysilane and 3(trimethoxysilyl)propyl-N,N,N-trimethylammonium chloride were purchased from Gelest,
Inc. (Morrisville, PA). Methoxy-poly(ethylene glycol)-block-poly(L-lysine hydrochloride)
(PEG-PLL, PEG MW 5000, PLL MW 4900) was purchased from Alamanda Polymers
(Huntsville, AL). HepG2, J774A.1, Renca, and SVEC4–10 cell lines were purchased from
ATCC (Manassas, VA). LIVE/DEAD assay kits were acquired from Life Technologies
Invitrogen (Grand Island, NY).

3.3.2 Gold nanoparticle synthesis
Sub-5 nm gold nanoparticles were synthesized via a modified Turkevich method
(Figure 3.2). Briefly, gold(III) chloride salt in water was reduced by dropwise addition of
sodium borohydride solution. After the mixture was stirred for 30 min, glutathione was
added to the solution to cap the nanoparticle surface. The resulting solution was washed
with deionized water three times in 10 kDa molecular cutoff centrifugation tubes and was
dispersed in PBS.

Figure 3.2 Schematic depiction of small glutathione-coated AuNP synthesis.
73

3.3.3 Tantalum oxide nanoparticle synthesis
Tantalum oxide nanoparticles (TaONP) were synthesized by a modified reverse
microemulsion method described by Kim et al.23 Tantalum(V) ethoxide solution was added
to 20 mL of cyclohexane-based microemulsion solution that contains 3 g of IGEPAL CO520

and

75

mM

NaOH

solution.

After

15

min,

250

uL

of

2-

(carbomethoxy)ethyltrimethoxysilane and 500 uL of 3-(trimethoxyysilyl)propyl-N,N,Ntrimethylammonium chloride were added to render the nanoparticle surfaces hydrophilic.
A white sediment formed at the bottom of the flask after 24 h of stirring. After the colorless
supernatant was carefully removed, the white sediment was dispersed in 5 mL of 5 M
ammonium hydroxide solution and stirred for 30 min. Subsequently, 25 mL of ultrapure
water was added and the resulting solution was allowed to stir at room temperature for 2
h. The resulting solution was then centrifuged at 2500g for 30 min. The clear solution in
the supernatant was further purified by centrifugation, washed with deionized water three
times at 2500g for 30 min in 10 kDa molecular cutoff centrifugation tubes, and dispersed
in PBS.

3.3.4 Cerium oxide nanoparticle synthesis
Small cerium oxide nanoparticles (CeONP) were synthesized by modifying an
alkaline-based precipitation method described by Perez et al (Figure 3.3).34 217 mg of
cerium nitrate hexahydrate salt dissolved in 4 mL of deionized water was mixed with 50
mg of poly(acrylic acid) polymer dissolved in 2 mL of deionized water. The resulting
mixture was then added to 95 mL of 0.4 M ammonium hydroxide solution. After being
stirred for 24 h, the solution turned from turbid light brown to clear yellow. The resultant
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nanoparticle solution was centrifuged at 2600g for 30 min, and the yellow supernatant was
collected. The supernatant was then washed with deionized water 5 times in 10 kDa
molecular cutoff centrifugation tubes and suspended in PBS.

Figure 3.3 Schematic depiction of poly(acrylic acid)-coated CeONP synthesis.

3.3.5 Polymetal nanoparticle synthesis
PCPP-based nanoparticles were synthesized on the basis of a method previously
reported by Cheheltani et al.35 A herringbone mixer microfluidic chip was utilized to yield
monodispersed and uniformly sized nanoparticles as shown in Figure 3.4. In this method,
2 mL of 0.1% (w/v) PCPP solution and 2 mL of 0.01% (w/v) spermine solution that also
contains 1.45 uL of 3.5% PEG-PLL (0.05 mg) were both prepared in PBS. The pH levels
of these solutions were adjusted to 7.4 before loading each solution in a 10 mL syringe.
Subsequently, both solutions were flowed through the mixer microfluidic chip at a flow rate
of 6 mL/min. The resultant output solution was then quickly added to 100 mL of 8.8% (w/v)
CaCl2 solution. After being stirred for 20 min, the solution was purified by centrifugation at
550g for 7 min in DI water three times. To encapsulate small nanoparticles in PCPP,
desired amounts of AuNP and CeONP were added to the PCPP solution, and TaONP
were added to the spermine and PEG-PLL solution before loading them in the syringes.
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The amounts of added PEG-PLL were varied from 0 to 0.2 mg to synthesize PMNP of
varying sizes.

Figure 3.4 Schematic illustration of PMNP synthesis using a microfluidic chip mixer.

3.3.6 Nanoparticle characterization
Transmission electron microscopy (TEM) was used to determine the core sizes
and morphologies of the small metal nanoparticles and PCPP nanoparticles. The images
were acquired using a Tecnai T12 microscope (FEI, Hillsboro, OR) or a JEOL 1010
microscope (JEOL Ltd., Tokyo, Japan). Diameters of 500 individual nanoparticles of each
formulation were manually measured on TEM images using ImageJ. The hydrodynamic
diameter and zeta potential of the nanoparticles were assessed by using a Nano-ZS-90
Zetasizer (Malvern Instruments, Worcestershire, UK) by preparing the samples at 0.2
mg/mL in concentration. The concentrations of the elemental payloads in the
nanoparticles were measured by using ICP-OES (Spectro Analytical Instruments GmbH,
Kleve, Germany).
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3.3.7 EDS elemental mapping
Energy-dispersive X-ray spectroscopy (EDS) imaging was used to confirm the
encapsulation of metal nanoparticles of all three elements and to investigate their spatial
distribution in an individual PMNP. A FEI Quanta 600 Environmental scanning electron
microscope (FEI, Hillsboro, OR) equipped with a Bruker Quantax Silicon Drift Detector for
EDS analysis was used. The samples were prepared on copper grids. M-edge energy
mappings were used for the presence of gold and tantalum and L-edge energy mapping
for the presence of cerium in the field of view. A mixed population of single metal PCPP
nanoparticles (SMNP), each encapsulating either AuNP, TaONP, or CeONP, was used
as a control to confirm the accuracy of elemental mapping.

3.3.8 In vitro polymetal nanoparticle degradation study
PMNP and SMNP (AuPCPP represents AuNP encapsulating PCPP nanoparticles,
TaPCPP represents TaONP encapsulating PCPP nanoparticles, and CePCPP represents
CeONP encapsulating PCPP nanoparticles) formulations at their maximum loading
capacities were added to 2 mL of PBS containing 10% fetal bovine serum at a
concentration of 0.15 mg/mL in payload elements (e.g., gold, tantalum, and cerium in
PMNP and gold in AuPCPP). The solutions were continuously flowed through platinum
cured silicon tubing that were 1.42 mm in internal diameter via a FH100M multichannel
peristaltic pump (Fisher Scientific, Hampton, NH) at a volumetric flow rate of 5 mL/min. At
days 1, 2, 4, and 7 of dynamic incubation, the solutions were collected and centrifuged at
500g for 5 min. The concentrations of gold, cerium, and tantalum in the supernatant and
the pellet were analyzed via ICP-OES to evaluate the release of small metal nanoparticles
at each time point. The amounts of released nanoparticles were calculated by dividing the
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concentration measured in the supernatant by the concentrations measured in both the
supernatant and the pellet. The samples were prepared in triplicates. TEM images of
partially degraded PMNP were also acquired to confirm the release of core nanoparticles.

3.3.9 In vitro cytocompatibility assessment
The LIVE/DEAD assay was used to evaluate the safety and cytotoxicity of the core
metal nanoparticles and the PCPP formulations with HepG2 (hepatocytes), Renca
(epithelial kidney cells), and SVEC4-10EHR1 (endothelial cells). The cells were cultured
in accordance with ATCC recommendations. 1.0 × 105 cells were seeded in each well of
24-well plates and were cultured for 24 h at 37 °C and 5% CO2. After 24 h of culture, the
medium was removed and replaced with fresh medium that contains the payload elements
of a range of concentrations (i.e., 0.025 mg/mL to 1 mg/mL). The cells were incubated
with the nanoparticle-treated media for 8 h before they were washed with DPBS and
treated with LIVE/DEAD stain (4 uL of 3.2 mM Hoechst 33343, 1 uL of calcein AM, and 2
uL of ethidium homodimer-1 in 2 mL of DPBS) for 20 min. The stained cells were imaged
with a Nikon Eclipse Ti-U fluorescence microscope. Images of cell nuclei, live cells, and
dead cells were acquired at four different fields of view in each well. The numbers of live
and dead cells were counted to calculate the cell viability in percentage (viability % = live
cell count/total cell count). The experiment was repeated three times for each cell line for
a total of 12 measurements per data point (n = 3, field of view = 4).

3.3.10 In vitro phantom CT imaging
Each PCPP formulation was suspended in 1% agar gel at concentrations of 0, 0.5,
1, 2, 4, 6, and 8 mg/mL (n = 3 per concentration). Each sample was prepared in a 0.2 mL
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flat cap microcentrifuge tube. These samples were secured in a plastic rack along with a
tube containing water and a tube containing no solution (or air) for μCT imaging. μCT
imaging was performed using a MILabs μCT scanner (MILabs, Utrecht, The Netherlands).
The images were acquired using a standard protocol with 0.1 mm beryllium and 0.5 mm
aluminum filtration, tube voltage of 50 kVp, tube current at 0.24 mA, step angle of 0.75°,
and exposure time of 75 ms. The identical samples were loaded in a custom-made,
acrylonitrile butadiene styrene tube holder that is designed to fit in the borehole of an
anthropomorphic thorax phantom body (QRM GmbH, Mohrendorf, Germany) for imaging
with a SOMATOM Force clinical CT scanner (Siemens Healthineers, Erlangen, Germany).
The phantom body mimics human organs in the thorax in terms of density, CT attenuation,
and size (200 × 300 × 200 mm). The CT images were acquired using a customized
protocol adapted from Siemens original adult abdomen routine imaging protocol at 80,
100, 120, and 140 kVp. The following parameters were used: beam filtration of 0.3 mm
titanium and 0.5 mm aluminum, anode angle of 8°, scan mode of helical acquisition, X-ray
tube current of 360 mA, exposure time of 0.5 s, slice thickness of 0.5 cm, and field of view
of 370 × 370 mm. For both μCT and CT imaging, the images were analyzed by using
OsiriX software (Pixmeo, Bernex, Switzerland). Circular ROIs were drawn on five different
axial planes of each tube. The mean attenuation values were recorded and normalized to
the values from our control tubes with 1% agar gel (i.e., 0 mg/mL solution). Attenuation
rate was defined by the slope of the linear regression line that models the linear
relationship between attenuation and elemental concentration in either mg/mL or mM.
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3.3.11 Simulation of payload element contribution to CT attenuation
A custom-written Python code was used to estimate the relative contribution from
each payload element to the CT attenuation of PMNP under imaging conditions used in
this study (i.e., 50 kVp in μCT imaging and 80, 100, 120, and 140 kVp in clinical CT
imaging). In this model, CT attenuation of PMNP is calculated using elemental attenuation
values of materials in PMNP (i.e., water, PCPP polymer, gold, tantalum, and cerium) from
National Institute of Standards and Technology (NIST), density of payload elements (i.e.,
gold, tantalum, and cerium), and estimated X-ray source spectra (beam filtration of 0.1
mm beryllium + 0.5 mm aluminum for μCT imaging and 0.3 mm titanium + 0.5 mm
aluminum for clinical CT imaging).

3.3.12 In vivo mice imaging
All animal experiments were performed in accordance with the protocols approved
by University Laboratory Animal Resources in conjunction with the Institutional Animal
Care and Use Committee at the University of Pennsylvania. In vivo CT images were
acquired from a MILabs μCT scanner, using the same scanning parameters from the
phantom imaging. After acquiring pre-injection images, C57BL/6J mice were injected with
either 40 μL of PMNP (n = 3) or AuPCPP (n = 3) containing 0.1 mg of the payload (i.e.,
gold in AuPCPP and gold, tantalum, and cerium combined for PMNP) and were scanned
again immediately after post-injection. Both formulations were injected in the left thigh
muscle of the mice. The acquired images were subsequently analyzed with Osirix. Using
a 3D region growing segmentation function, 3D regions of interest (ROI) that enclosed the
injection sites were isolated and highlighted. The total attenuation that was generated by
either AuPCPP or PMNP was quantified by addition of the attenuation values (in
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Hounsfield Unit) of each voxel within the 3D ROI and subtraction of the total attenuation
generated by the soft tissue from the pre-injection scan from this number.

3.3.13 Statistical analysis
The slope (mχ) and the standard error of fit (eχ) of attenuation rates from μCT and
CT were calculated using the least-squares method of linear regression. One-way analysis
of variance (ANOVA) was used to test if there is an overall difference between the groups
in safety and cytotoxicity, payload loading ratio, biodegradability, and attenuation rates. In
cases in which the p-value from the ANOVA test indicated that there is an overall
significant difference between the groups (p ≤ 0.05), Tukey–Kramer HSD (honestly
significant difference) posthoc test was used to confirm which specific pairs of groups had
significant differences. A two-sample t test was used to compare total attenuation
generated by PMNP and AuPCPP from in vivo imaging. Error bars in the graphs represent
one standard deviation unless indicated otherwise.

3.4 Results
3.4.1 Core nanoparticles syntheses and characterization
Small core nanoparticles, AuNP, TaONP, and CeONP, were synthesized and
capped with ligands that provide hydrophilicity and stability in biological fluids. The core
sizes of AuNP, TaONP, and CeONP were determined to be 3.7 ± 0.7, 4.8 ± 0.7, and 2.8
± 0.6 nm, respectively, while their hydrodynamic diameters were slightly larger in each
case (Figure 3.5 A,B). The zeta potentials of AuNP and TaONP that were both capped
with ligands of zwitterionic charges were closer to neutral when compared to that of
CeONP, which was capped with negatively charged poly(acrylic acid).
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Figure 3.5 Characterization of small core metal nanoparticles of PMNP.
(A) TEM of small core metal nanoparticles and photos of the corresponding nanoparticles
at concentrations of 1, 5, and 10 mg/mL (top right insets). (B) The core and hydrodynamic
diameters and surface charge of the small core metal nanoparticles.

3.4.2 In vitro cytocompatibility of core nanoparticles
The safety and cytotoxicity of these small metal nanoparticles were assessed by
incubating them with cell types that would likely have the highest exposure upon
intravenous injection (i.e., endothelial cells (SVEC4-10EHR1), liver hepatocytes (HepG2),
and kidney cells (Renca)) for 8 h. While there were statistically significant differences for
some of the treatment concentrations for TaONP and CeONP for all cell types when
compared to the control groups (0 mg/mL), the lowest cell viability observed was 96.2 ±
3% (for Renca cells incubated with TaONP at 1.0 mg Ta/mL), indicating that the reductions
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were not substantial (Figure 3.6). These results justified the use of these nanoparticles in
the next steps of this study.

Figure 3.6 In vitro cell viability of small nanoparticles.
Normalized cell viability of SVEC4, HepG2, and Renca after 8 h of incubation with AuNP,
TaONP, and CeONP (n.s. = not significant or p > 0.05, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤
0.001 as compared to the control group (0 mg/mL)).

3.4.3 Encapsulation of core nanoparticles for polymetal nanoparticle synthesis
The aforementioned AuNP, TaONP, and CeONP formulations were successfully
incorporated into PCPP nanoparticles either individually to form SMNP or jointly to form
PMNP. We assessed the loading capacity of both SMNP and PMNP that are synthesized
with addition of 25 μg PEG-PLL/mg PCPP (which results in unloaded PCPP nanoparticles
with an average diameter of 102.4 nm). In the case of AuPCPP, more than 5 mg of gold
payload could be encapsulated per mg of PCPP polymer used during the synthesis
without deviation from spherical morphology (Figure 3.7A). Similarly, up to 1.25 mg of
tantalum and 0.375 mg of cerium per mg of PCPP could be loaded in their corresponding
SMNP formulations (Figure 3.7B,C). Less tantalum and cerium incorporation can be
explained by their lower elemental densities (dTa = 16.6 g/cm3, dCe = 6.8 g/cm3) when
compared to the density of gold (dAu = 19.3 g/cm3) and the presence of other constituents
in the core of TaONP and CeONP (i.e., oxygen atoms). When AuNP, TaONP, and CeONP
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at equal concentrations were encapsulated collectively to form PMNP, a maximum of 1
mg of total payload (gold + tantalum + cerium) per mg of PCPP polymer could be loaded
without disrupting the morphology (Figure 3.7D,E). At the maximum loading capacity, the
mean diameter of PMNP increased by 35% when compared to that of non-loaded PCPP
nanoparticles (Figure 3.8). As seen in both SMNP and PMNP, incorporation of higher
payloads increased the diameter of PCPP nanoparticles.
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Figure 3.7 TEM of SMNP and PMNP.
TEM of A) AuPCPP, B) TaPCPP, C) CePCPP, and D) PMNP with various loadings of core
nanoparticles. E) TEM of overloaded PMNP, TaPCPP, and CePCPP formulations. Scale
bar = 100 nm.

Figure 3.8 Payload-dependent increase of diameters.
Payload dependent increase of SMNP and PMNP in diameter. The one-side error bar
represents a standard deviation of the corresponding diameter.

Although the ratio of incorporated payloads of different elements can be freely
adjusted, the PMNP formulations reported herein were synthesized with 1:1:1 mass ratios
of gold:tantalum:cerium payloads. To assess the relative ratios of these elements
encapsulated in PMNP, their concentrations were analyzed by ICP-OES. As shown
in Figure 3.9A, the ratios of elements loaded in PMNP were similar to the input ratios.
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Figure 3.9 Encapsulation of small core nanoparticles in PMNP.
(A) Relative percentages of each payload at maximum loading in PMNP (1 mg
Au,Ta,Ce/mg PCPP) (* = p ≤ 0.05). (B) SEM brightfield images, EDS mappings of gold,
tantalum, and cerium, and overlay images. Scale bar = 200 nm.

3.4.4 Spatial distribution of core nanoparticles in polymetal nanoparticles
PMNP was analyzed with EDS mapping to further investigate the encapsulation of
all three elements and to examine the spatial distribution of these elements in individual
PMNP. To ensure the accuracy of elemental mapping, we used a mixed population of
SMNP as a control. As seen in Figure 3.9B, SMNP loaded with either gold, tantalum, or
cerium could be successfully differentiated from one another in our control group. Each
element was located in its corresponding SMNP formulation without any overlap, allowing
us to identify the loading element in each SMNP accurately. On the other hand, for PMNP,
all three elements were detected in every PCPP nanoparticle. The elemental maps were
colocalized to the location of PCPP nanoparticles in the brightfield image in both groups
as well. These data suggest successful co-encapsulation of all three small core
nanoparticles into each individual PMNP.
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3.4.5 Size control of polymetal nanoparticles
As demonstrated in Figure 3.10, the size of PMNP (0.5 mg Au,Ta,Ce/mg PCPP)
could be controlled in the range of 50–450 nm by varying the amount of PEG-PLL used
during the synthesis from 0 to 0.2 mg per mg of PCPP. The average diameter of PMNP
decreased with increasing amounts of PEG-PLL in a nonlinear manner. This is due to the
fact that addition of PEG-PLL limits the growth of PCPP nanoparticles as reported in our
previous study with non-loaded PCPP nanoparticles.35

Figure 3.10 Relationship between size of PMNP and amount of PEG-PLL during
synthesis.
(A) Effect of PEG-PLL on PMNP diameter. (B) TEM of PMNP of different sizes. Scale bar
= 200 nm.
3.4.6 In vitro biodegradability
For eventual excretion of PMNP, the small core nanoparticles in PMNP would need
to be released from their polymeric components effectively. We therefore evaluated the
release rate of the core nanoparticles by incubating PMNP in 10% fetal bovine serum in
PBS at 37 °C for 1, 2, 4, and 7 days. The PMNP solution was constantly flowed through a
tubing during the incubation periods to mimic the dynamic nature of blood and interstitial
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fluid. We observed that approximately 90% of AuNP, TaONP, and CeONP was released
from PMNP in 7 days, demonstrating the degradability of PMNP and the effective release
of its core nanoparticles (Figure 3.11A). Unlike SMNP formulations that showed clear
differences in the release pattern of their core nanoparticles (Figure 3.11B), the release
rates of the three core nanoparticle formulations in PMNP were comparable to each other,
indicated by much smaller statistical differences throughout the study period. More rapid
release of CeONP from CePCPP can be explained by the smaller hydrodynamic diameter
of CeONP and possibly their strong negative surface charge. TEM of partially degraded
PMNP confirmed the dissociation and the release of core nanoparticles from PMNP
(Figure 3.11C).

Figure 3.11 Release of small core nanoparticles from PMNP in vitro.
Payload release from (A) PMNP and (B) SMNP. (C) TEM of partially degraded PMNP after
4 days of dynamic incubation (n.s. = not significant or p > 0.05, * = p ≤ 0.05, ** = p ≤ 0.01,
*** = p ≤ 0.001).

3.4.7 In vitro cytocompatibility of polymetal nanoparticles
The safety and cytotoxicity of PMNP as well as of AuPCPP, TaPCPP, and
CePCPP were evaluated using the same method used to assess the safety and
cytotoxicity of the small core nanoparticles (Figure 3.12A,B). Once again, incubation of
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the selected cell lines with PMNP and SMNP formulations for 8 h did not considerably
affect cell viability when compared to the control groups (0 mg/mL). The lowest mean cell
viability observed from PMNP incubation was 96 ± 2% in Renca cell line at a treatment
concentration of 1 mg Au,Ta,Ce/mL. The results of high cell viability from both small core
nanoparticles and PCPP formulations suggest that PCPP polymer and its byproducts do
not have significant cytotoxicity, which agrees with the previous findings.35-37

Figure 3.12 Cell viability after SMNP and PMNP treatment.
Effect of (A) SMNP and (B) PMNP on cell viability after 8 hrs of incubation (n.s. = not
significant or p > 0.05, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001 as compared to the
control group (0 mg/mL)).

3.4.8 In vitro CT contrast generation
We next assessed PMNP’s CT contrast properties using both a μCT scanner and
a clinical CT scanner. A MILabs μCT scanner with a tube voltage of 50 kVp was used to
scan both SMNP and PMNP of increasing element concentration (e.g., gold in AuPCPP
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and gold, cerium, and tantalum combined in PMNP) (Figure 3.13A,B). All of the
formulations had linear correlations between the attenuation and the concentration
with R2 values >0.99 in each case (the data for PMNP are shown in as an example in
Figure 3.13C). From the attenuation rate measurements, we found that PMNP and
AuPCPP had the highest values, followed by TaPCPP and CePCPP. The attenuation rate
of PMNP was not statistically significantly different from that of AuPCPP (Figure 3.13D).

Figure 3.13 In vitro contrast generation of PMNP and SMNP in μCT imaging.
Phantom images of (A) SMNP and (B) PMNP from a MILabs μCT system. (C) Attenuation
of PMNP at a range of concentrations. (D) Attenuation rates of different PCPP
formulations (n.s. = not significant or p > 0.05, *** = p ≤ 0.001).
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The same PCPP formulations were scanned in a SOMATOM Force clinical CT
scanner at four different tube voltages of 80, 100, 120, and 140 kVp. The solutions were
scanned in an anthropomorphic phantom body that closely mimics the thorax of a patient
(20 cm × 30 cm × 20 cm) to improve the clinical relevance of the data. An axial plane
image of the phantom body containing SMNP and PMNP solutions at a tube voltage of
120 kVp is shown in Figure 3.14A and B, in which the increase in attenuation is clearly
observed with increasing concentration of the payload. In validation of the images, an
excellent linear correlation between the attenuation and the concentration was observed
(Figure 3.14C). As expected, we observed that the attenuation rates of both SMNP and
PMNP depended heavily on the tube voltage (Figure 3.14D).

Figure 3.14 In vitro contrast generation of PMNP and SMNP in clinical CT imaging.
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Phantom images (A) SMNP and (B) PMNP samples from a SOMATOM Force CT scanner
and enlarged images centered at the PCPP samples. (C) Attenuation of PMNP at a range
of concentrations. (D) Attenuation rates of different PCPP formulations at different tube
voltage settings derived from a clinical CT scanner (n.s. = not significant or p > 0.05, ***
= p ≤ 0.001).

The attenuation rates of AuPCPP were the lowest across all four tube voltages in
this study and the attenuation rates of TaPCPP remained higher than those of AuPCPP
across all tube voltages. TaPCPP’s attenuation rate slightly increased from 80 to 100 kVp
before decreasing again at higher tube voltages of 120 and 140 kVp. Unlike AuPCPP and
TaPCPP, a steep decrease in attenuation rate was observed for CePCPP with increasing
tube voltage. Its attenuation rate was the highest at 80 kVp; however, due to cerium’s
comparatively low K-edge energy of 40.4 keV, its attenuation rate sharply decreased to
lower than that of TaPCPP at 140 kVp. Interestingly, PMNP also exhibited a decline in
attenuation rate with increasing tube voltage. However, the rate of decline was much lower
than that of CePCPP, which resulted in its attenuation rate being the second highest after
CePCPP at 80 kVp to the highest in both 120 and 140 kVp. Similar trends were observed
when attenuation rates were calculated on the basis of molar concentration of the PCPP
formulations. Notably, the attenuation rates of PMNP were higher than those of other
formulations across all tube voltages used in our study with the exception of TaPCPP at
120 kVp (Figure 3.15).
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Figure 3.15 CT contrast properties of PCPP formulations.
Attenuation rates of different PCPP formulations derived from a SOMATOM Force CT
scanner based on molar concentration (n.s. = not significant or p > 0.05, * = p 0.05, ** = p
≤ ≤ 0.01, *** = p 0.001).

3.4.9 Relative contribution to CT attenuation
Using NIST attenuation coefficients of payload elements and X-ray source energy spectra,
we calculated the attenuation that was produced by each payload element in PMNP. The
relative attenuation contributions from each payload elements were comparable to the
differences in attenuation rates between SMNP formulations in our phantom imaging study
(Figure 3.16). Attenuation from gold was the largest followed by tantalum and cerium,
respectively, in 50 kVp for μCT imaging simulation. The relative attenuation ratio of cerium
decreased and those of gold and tantalum slowly increased as the tube potential
increased in clinical CT imaging simulation. Interestingly, the relative ratios of contribution
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between gold and tantalum were very similar to one another across all tube potentials
used in this study.

Figure 3.16 Relative attenuation contribution of gold, tantalum, and cerium to PMNP.
Simulated relative contribution from gold, tantalum, and cerium to PMNP’s CT attenuation
at 8 mg/ml in payload element concentration from µCT and clinical CT imaging with
various tube potential settings used in this study.

3.4.10 In vivo contrast generation
In vivo contrast properties of PMNP were assessed by imaging mice that were
intramuscularly injected with the same dose and volume (0.1 mg, 40 μL) of either PMNP
or AuPCPP - two formulations that showed the highest attenuation rates in μCT phantom
imaging. As shown in Figure 3.17A–C, ROI of contrast agents surrounding the injection
site were isolated and highlighted in both 2D and 3D images, which was possible due to
production of strong CT contrast by these contrast agents. The highlighted area could also
be accurately depicted in 3D isocontour mapping for better visualization of its volume
(Figure 3.17D). To quantify and compare the contrast generation by PMNP and AuPCPP,
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total attenuation (summation of CT attenuation values in each voxel) of the isolated 3D
ROI was measured. In agreement with our findings in μCT phantom imaging, the total
attenuation generated by PMNP had no statistically significant difference from the total
attenuation measurement of AuPCPP (Figure 3.17E).

Figure 3.17 In vivo images and contrast generation analysis.
CT images of PMNP injected in the thigh muscle viewed in the (A) axial plane and the (B)
sagittal plane. Insets represent enlarged images of injected PMNP highlighted in light blue.
(C) 3D rendered CT image of a mouse with the PMNP injection site highlighted in light
blue. (D) Isocontour depiction of injected PMNP in both axial and sagittal views. (E) Image
analysis of the attenuation arising from nanoparticle injections (n.s. = not significant).

3.5 Discussion
In this study, by encapsulating small core nanoparticles made of three different
elements (gold, tantalum, and cerium) in PCPP polymer, we developed biodegradable
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polymetal nanoparticles that can generate high CT contrast at various tube voltage
settings used in both μCT and clinical CT scanners. Our phantom and in vivo mice imaging
study results both support that contrast agents made of several elements with suitable Kedge energies can generate consistently high attenuation in CT imaging of various X-ray
source spectra, similar to the effects observed in radioprotective garments. In fact, our
PMNP formulation generated significantly higher attenuation than well-studied
experimental CT contrast payload materials, such as gold and tantalum alone, in different
tube potential settings used in this study. The attenuation rates of PMNP observed in our
study are also much higher than those of iodinated contrast agents (i.e., iopamidol)
reported by Hsu et al.,38 who acquired the data with the identical CT scanner, tube voltage,
and other scanning parameters. The high attenuation generation of our PMNP formulation
throughout low and high tube voltage settings can offer an advantage over the use of
payload elements of low K-edge energies, such as cerium and iodine, in numerous CT
imaging applications. These low K-edge energies suffer from deterioration of attenuation
generation at high tube voltage (e.g., 140 kVp).39 This indicates that our PMNP formulation
can especially be beneficial in CT imaging of obese patients, a rapidly growing patient
pool,40 which often requires imaging at high tube voltage.41,42 Most studies of novel CT
contrast agent development focus on either small molecules or nanoparticles made of
single element payloads. However, the observations made in this study indicate that the
development of CT contrast agents with two or more CT payload elements can potentially
improve their CT contrast properties. Future investigation of the amount, ratio, and
identification of different payload elements (e.g., gadolinium and ytterbium) will further
enhance the CT contrast properties of PMNP. As shown in our simulation, ideal ratios and
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choices of payload elements can be predicted with sufficient accuracy to make PMNP
suitable for user-specific CT imaging applications.
In our design of PMNP, we have loaded the hydrophilic core nanoparticles in PCPP
polymers. However, various kinds of platforms capable of serving as carriers for multiple
contrast generating materials are available. These platforms include micelles, liposomes,
nano- and micro-emulsions, dendrimers, lipoproteins, and other polymeric nanoparticles
(e.g., PLGA, alginate), all of which have previously been demonstrated to be effective
carriers of contrast payloads.43-48 Many of these platforms, such as liposomes and
lipoproteins, are also capable of containing both hydrophilic and hydrophobic payloads,
further expanding the choices of payload materials for the synthesis of polymetal
nanoparticles.
Our previous studies have loaded small gold nanoparticles in PCPP
nanoparticles.35,49 However, this study was the first attempt to include core nanoparticles
of three different elements. This new formulation can lead to increased affordability as
compared to other leading experimental CT contrast agents (e.g., AuNP), reduced doserelated cytotoxicity, and most importantly, improved CT attenuation production. As
mentioned above, the potential for PMNP to be a contrast agent with excellent CT contrast
properties has been demonstrated; however, more work is still needed to develop PMNP
into a blood pool agent with desired pharmacokinetics and sufficient excretion of its
payloads. The possibility of achieving sufficient excretion is promising, considering the
versatility of PCPP-based nanoparticles. By adjusting the amount of PEG-PLL added, the
diameter of PMNP could be controlled. The side-chain groups and the molecular weight
of PCPP can also be readily adjusted, allowing us to control PMNP’s degradation rate and
its diameter at ease.50 Other components of the synthesis (e.g., cross-linker) can be

98

changed as well. For instance, spermine (polyamine with four amine groups) can be
replaced with alternative polypeptides with less cationic properties for faster degradation.
To ensure the feasibility of its use as a safe CT blood pool agent, more extensive studies
on long-term cytotoxicity of PMNP will need to be done. Its plausibility for successful
injection in human patients will also need to be investigated in the future. Sufficiently high
concentration of PMNP could easily be reached for in vivo mice injection in our study, but
hundreds of mg/mL in payload concentration will be needed for human subject injection.
While this is possible, the viscosity and osmolarity of PMNP solutions at these levels of
concentrations will need to be assessed. Finding gold, tantalum, and cerium nanoparticle
formulations that are coated with surface ligands that result in higher payloads PCPP
nanoparticles (i.e., hydrophilic, anionic) will be crucial, as it will decrease the amount of
polymer needed in the formulation and subsequently decrease the viscosity.
Widely studied experimental CT contrast agents, such as AuNP, have also been
utilized as an X-ray radiosensitizer due to their large X-ray interaction cross section,
leading to better energy and radiation deposition for effective induction of local tumor cell
death.51,52 PMNP’s ability to produce higher CT attenuation in various tube voltage settings
in the keV region supports the idea that PMNP can potentially be more effective in energy
deposition, and therefore can act as a better radiosensitizer than AuNP. Potential use of
PMNP is not limited to CT and X-ray based biomedical applications. The payload materials
of multiple imaging modalities (e.g., quantum dots for fluorescence imaging and iron oxide
nanoparticles for MR imaging) can be loaded in PMNP for multimodal imaging; hydrophilic
drugs can be co-loaded with contrast agents for theranostics.
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3.6 Conclusion
In summary, we developed a unique design of polymetal nanoparticles by
encapsulating hydrophilic, small core metal nanoparticles that are made from three
different contrast generating elements - gold, tantalum, and cerium - in PCPP polymer
carriers. PMNP demonstrated efficient loading of hydrophilic payloads, encapsulating up
to 1 mg of contrast generating materials per mg of PCPP polymer while maintaining its
structural stability, biocompatibility, and biodegradability. We have also shown that the
PMNP formulation is a robust CT contrast agent that can generate higher attenuation in
both μCT and clinical CT imaging in various scanning conditions, when compared to its
single payload counterparts. Our promising results in the contrast properties of PMNP
suggest that the development of platforms carrying multiple contrast generating materials
can further improve CT contrast, and therefore can benefit CT imaging in various
biomedical applications.
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CHAPTER 4: CITRIC ACID COATED CERIUM OXIDE NANOPARTICLES
FOR DETECTION AND TREATMENT OF INFLAMMATORY DISEASES
4.1 Abstract
Cerium oxide nanoparticles (CeONP), having potent antioxidant properties, are
highly promising for treatment of diseases in which oxidative stress from excessive
reactive oxygen species (ROS) plays a critical role in the pathogenesis and progression.
However, previously reported CeONP formulations were not cleared from the body,
precluding their clinical translation. Herein, we report renally clearable ultrasmall CeONP
that can mitigate acute inflammation. It was found that these CeONP can effectively
scavenge reactive species, inhibit immune cell activation, and minimize their recruitment
and infiltration to the inflammation site, which led to alleviation of persistent inflammatory
reaction and pain hypersensitivity. Moreover, we demonstrate that CeONP can be
effectively excreted from the body within 24 hours of systemic administration, minimizing
long-term toxicity concerns. Cerium’s appropriate K-edge energy also makes CeONP
suitable contrast agents for CT imaging. Therefore, we also investigated the potential use
of CeONP as CT contrast agents by performing phantom imaging studies. Altogether, our
findings suggest that CeONP can be used as an effective antioxidant and
immunomodulatory agent to reduce collateral healthy tissue damage during acute
inflammation with an improved safety profile and as a CT contrast agent for disease
diagnosis.
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4.2 Introduction
ROS is a natural byproduct of oxygen metabolism that is essential for cell
signaling; however, production of excess ROS and other free radicals (i.e., reactive
nitrogen species or RNS) can have detrimental effects to cells, causing oxidative damage
to various cellular components, such as DNA, proteins and lipids, and subsequently
leading to cell death and tissue damage.1 The elevated production of free radicals (e.g.,
superoxide, hydroxyl radical and nitric oxide) from the imbalance between their production
and their elimination by endogenous catalytic mechanisms is defined as oxidative stress.2,
3

Oxidative stress is a key contributor in progression of inflammatory diseases as well as

acute injury and inflammation.4 It is previously found that oxidative stress promotes
inflammation by directly activating the genes that are involved in inflammatory pathways
(e.g., NF-κB/AP-1) to induce secretion of proinflammatory cytokines and inhibit tissue
remodeling.5 Furthermore, inflammatory processes promote ROS production from
phagocytic cells (e.g., macrophages and neutrophils), which can cause additional tissue
injury and subsequently initiate further immune response and ROS production as a
result.4, 6 Therefore, restoration of free radical homeostasis via antioxidant treatment is a
promising therapeutic approach to modulate collateral tissue damage from oxidative
stress and inflammation.
An emerging field that can offer a novel treatment option for oxidative stressrelated diseases is the development of nanozymes.7 Nanozymes are capable of mimicking
the catalytic activities of natural enzymes to efficiently scavenge free radicals in their
surroundings. An example of a class of nanozyme is CeONP, which are inorganic
nanoparticles that have attracted substantial research interest due to their potent and
recyclable ROS scavenging activities.8-13 Cerium ions in CeONP can exist in one of two
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oxidation states (Ce3+ and Ce4+) on the nanoparticle surface; and highly mobile oxygen
vacancies in the lattice allow these cerium ions to freely alternate their oxidation states to
either lose or gain oxygen atoms in a reversible manner.14-16 Through this interchange in
redox state, each reactive site on CeONP can interact with numerous ROS and convert
them to inert molecules. This allows CeONP to have more potent antioxidative activities
than traditional antioxidants (e.g., vitamin C and selenium) that are exhausted after
interaction with one molecule of reactive species. In addition, the presence of multiple
reactive sites on the nanoparticles surfaces further augments the antioxidant properties of
CeONP to allow sustained ROS scavenging activity.
CeONP’s strong catalytic activity through the redox reaction has already been wellrecognized and widely applied in petrochemical and materials industry as fuel cells,
oxygen sensors, ultraviolet absorbents, to name a few.17-19 More recently, CeONP have
been increasingly explored for various biomedical applications in treatment of ROS-related
diseases, which include, but are not limited to, neurodegenerative diseases,20,

21

autoimmune diseases,22 ocular surface diseases,13 and ischemic and acute injuries.23-25
Biomedical applications of CeONP is supported by the fact that the afore-mentioned ROS
scavenging mechanisms are analogous to biological processes used by endogenous
enzymes in our body, such as superoxide dismutase (dismutation of superoxide anion into
molecular oxygen and hydrogen peroxide) and catalase (oxidation of hydrogen peroxide
to water and oxygen molecules).26-28
By designing our CeONP formulation to be ultrasmall, we further improved the
feasibility of the formulation’s use in biomedical applications and eventual clinical
translation. The average hydrodynamic diameter of our CeONP formulation (~ 3 nm) is
well-below the putative renal filtration threshold of 5.5 nm, promoting efficient renal
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clearance and thereby avoiding toxicity concerns that arise from long-term retention in the
reticuloendothelial system (e.g., liver and spleen).29, 30 The ultrasmall size also raises the
surface area-to-volume ratio, which subsequently increases the number of reactive sites
per dose of cerium to enhance the efficacy of ROS scavenging per material used. The
surface coating used (i.e. citric acid) was also able to provide stability in biological media
without interfering the catalytic activities of CeONP.
Cerium, the main elemental composition of CeONP, is a lanthanide heavy metal
element that has a favorable K-edge energy for high contrast generation in CT imaging.
Its K-edge energy (40.4 keV) is located in a high X-ray photo flux region, resulting in
greater CT contrast production when compared to iodine, whose K-edge energy is at 33.2
keV. Cerium’s biocompatibility, low cost (especially when compared to gold, which is the
most widely studied element for experimental CT contrast agent development), wide
availability also make it practical to use on a large scale with high potential for clinical
translation. However, despite these advantages, cerium and cerium-based nanoparticles
have not been extensively studied as CT contrast agents.
Herein, we demonstrate that citric acid coated CeONP with strong antioxidant
properties can alleviate acute inflammation by reducing secretion of pro-inflammatory
cytokines and suppressing macrophage recruitment to the inflammation site. Moreover,
we investigate the toxicity and renal clearance of the CeONP formulation, which are key
parameters to be considered for eventual clinical translation.

We also examine CT

contrast generation of citric acid coated CeONP to assess their feasibility to be developed
as CT contrast agents.
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4.3 Materials and methods
4.3.1 Materials
Cerium(III) nitrate hexahydrate (99.99%) and ammonium hydroxide (28.0−30.0%
NH3 basis) were obtained from Sigma-Aldrich. Citric acid anhydrous, superoxide
dismutase colorimetric activity kit, Amplex red hydrogen peroxide/peroxidase assay kit,
CM-H2DCFDA, Griess reagent kit, mouse TNF alpha and IL-1 beta ELISA kits were
purchased from Thermofisher Scientific. Mouse IL-10 ELISA kit was acquired from Abcam.
HepG2, RAW 264.7, Renca, SVEC4-10EHR1 cell lines were purchased from ATCC.

4.3.2 Synthesis of citric acid coated CeONP
Ultrasmall citric acid coated CeONP were synthesized by slight modification of an
alkaline-based precipitation method that our group has previously reported.31 Briefly, a 4
ml solution containing 217 mg of cerium nitrate precursor was mixed with a 2 ml solution
containing 200 mg of citric acid. The resulting mixture was quickly added to 100 ml of 0.4
M ammonium hydroxide. After 24 hours of stirring at room temperature, the resulting clear
yellow nanoparticle solution was centrifuged at 2600 g for 30 minutes to remove
aggregates. The supernatant of the centrifuged solution was further purified by
centrifugation in 3 kDa molecular weight cutoff tubes. This purification step was repeated
5 times by resuspending the concentrated solution in deionized water to remove any
unreacted chemicals. The resulting nanoparticle solution was ultra-centrifuged at 15000 g
for 10 minutes and was subsequently filtered through a 0.02 µm syringe filter. The final
nanoparticle solution was suspended in either deionized water or PBS for further studies.
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4.3.3 Nanoparticle characterization
The UV-visible absorbance spectrum of CeONP was obtained using a Genesys
UV/visible (Thermofisher Scientific) spectrophotometer. The core sizes and morphologies
of CeONP were determined using transmission electron microscopy (TEM). A Tecnai T12
microscope (FEI) was operated at 100 kV to acquire the micrographs. ImageJ software
was used to manually measure the diameters of 500 individual nanoparticles for core size
analysis. A Nano-ZS Zetasizer system (Malvern Instruments) was used to measure the
hydrodynamic diameters and zeta potentials. The concentration of CeONP solution was
measured by using ICP-OES (Spectro Analytical Instruments GmbH). The X-ray
diffraction (XRD) pattern of dried CeONP was characterized by a Rigaku GiegerFlex
D/Max-B X-ray diffractometer in the range of 20° to 90° at a scan rate of 2° per minute.
For energy-dispersive X-ray spectroscopy (EDX), CeONP were dried onto a copper grid
before recording their EDX spectra using a Quanta 600 field emission gun scanning
electron microscope. A JASCO FT/IR-480 Plus spectrophotometer was used to collect the
infrared spectra of CeONP and citric acid powder. The samples were prepared by grinding
dried CeONP solution into powder with dried potassium bromide and pressing into a
compact pellet.

4.3.4 In vitro phantom CT imaging
CeONP, cerium nitrate precursor salt, glutathione-coated gold nanoparticles and
iopamidol were suspended in water at a range of concentrations (0.5 to 8 mg Ce/ml) in
0.2 ml flat cap microcentrifuge tubes. For imaging in a SOMATOM Force clinical CT
scanner (Siemens Healthineers, Germany), the tubes were placed in a 3D printed tube
holder that was designed to fit in the borehole of an anthropomorphic thorax phantom
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body (QRM GmbH, Germany). The phantom body mimics human thorax in dimension (20
x 30 x 20 cm), the organ density and CT attenuation. The following parameters were used
to acquire the CT images: helical acquisition at tube potentials of 80, 100, 120 and 140
kVp, tube current of 360 mA, beam filtration of 0.3 mm titanium and 0.5 mm aluminum,
exposure time of 0.5 s, slice thickness of 0.5 cm, and field of view of 370 × 370 mm. The
CT images were analyzed using OsiriX software (Pixmeo, Switzerland). Circular ROIs
were drawn on five slices of the axial plane for each tube. The mean attenuation values
were normalized to the water tubes. The slope of the linear regression line between
attenuation and sample concentration was used as the attenuation rate.

4.3.5 In vitro cytocompatibility
The

biocompatibility

of

CeONP

with HepG2

(hepatocytes),

RAW264.7

(macrophages), Renca (epithelial kidney cells) and SVEC4-10EHR1 (endothelial cells)
was assessed by measuring the cell viability after CeONP treatment. Each cell line was
seeded at 1 × 105 cells/well in 24-well plates and was cultured overnight. After the initial
cell culture, the media was exchanged with fresh media with various concentrations of
CeONP (0, 0.1, 0.25, 0.5, 1, 2.5 mg Ce/ml). The cells were incubated in the CeONPtreated media for 24 hours prior to media removal and addition of LIVE/DEAD stain. The
cells were stained for 20 minutes for fluorescent imaging of cell nuclei, live cells and dead
cells at four different fields of view per well. The cell viability was calculated by dividing the
live cell count by the total cell count.
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4.3.6 Superoxide dismutase and catalase mimetic activity assays
SOD-mimetic activity of CeONP was measured with a SOD colorimetric activity kit
(Invitrogen). CeONP stock solution was diluted to varying concentrations ranging from
0.01 to 1 mg Ce/ml in PBS. 10 µl of each concentration were added to the wells of a 96well plate. Upon subsequent additions of the substrate and xanthine oxidase to the wells
per instruction, the mixture was incubated at room temperature for 20 minutes before
reading the absorbance at 450 nm. Catalase-mimetic activity of CeONP was conducted
with an Amplex red hydrogen peroxide/peroxidase assay kit (Molecular Probes, Inc.).
CeONP solutions of varying concentrations ranging from 0.01 to 1 mg Ce/ml were
prepared in the reaction buffer. After adding 50 µl of CeONP to the wells of a 96-well plate,
50 µl of 40 µM hydrogen peroxide was subsequently added. After 20 minutes of
incubation, 50 µl of working solution (100 µM 10-acetyl-3,7-dihydroxyphenoxazine and 0.2
U/ml horseradish peroxide) was added to each well. The mixture was allowed to react at
room temperature for another 30 minutes before reading the absorbance at 560 nm.

4.3.7 Intracellular ROS and RNS (reactive nitrogen species) production level
The cellular levels of ROS in macrophages were measured by using a ROS
sensitive dye, chloromethyl 2’7’-dichlorodihydrofluorescein diacetate (CM-H2DCFHDA).
RAW 264.7 macrophage cells were seeded in 96-well plates at a density of 2 × 104
cells/well and were cultured overnight. Then, the cell culture media was exchanged with
fresh media for the LPS- group and fresh media with 200 ng/ml of LPS for the LPS+ groups
to start lipopolysaccharide (LPS) stimulation. After 1 h, CeONP solutions of different
concentrations (i.e., 0 mg/ml for the LPS- group and 0, 0.01, 0.05, 0.1, 0.5 or 1 mg/ml for
the LPS+ groups) were added to the cell culture media, and the cells were further
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incubated for another 23 hours. To end LPS stimulation and CeONP treatment, the cells
were washed twice with PBS before incubating with 10 uM of CM-H2DCFHDA solution for
20 minutes at 37 °C. At the end of dye incubation, RAW 264.7 cells were washed with
PBS once before being resuspended in PBS to allow cells to recover for 5 minutes at 37
°C. The fluorescence intensity was measured at excitation wavelength of 492 nm and
emission wavelength of 527 nm.
The identical cell culture and treatment conditions were used to assess the
production levels of RNS (i.e., nitric oxide) by RAW 264.7 macrophages. A Griess Reagent
kit (Invitrogen) was used to detect the nitrite concentrations. After the LPS stimulation and
CeONP treatment, 100 µl of cell culture media was collected and mixed with an equal
volume of Griess reagent (N-(1-naphthyl)- ethylenediamine, sulfuric acid and deionized
water). After 30 minutes of incubation at room temperature, the absorbance was
measured at 548 nm.

4.3.8 Pro- and anti-inflammatory mRNA expression
mRNA expression and cytokine release levels of both pro-inflammatory cytokines
(TNFα and IL-1β) and anti-inflammatory cytokine (IL-10) from RAW 264.7 macrophages
were assessed. The cells were seeded at a density of 1 × 106 cells/well in 6-well plates
and were cultured overnight. At which point, the media was removed and replaced with
fresh media with or without LPS to start the LPS stimulation. The LPS and CeONP
treatment conditions were identical to the previous setup in ROS and RNS assessment.
At the end of the treatment, the media were removed to evaluate the cytokine levels of
TNFα, IL-1β and IL-10 via ELISA kits. The cells were also separately collected for the
assessment of their mRNA expression levels. Total RNA isolated from RAW 264.7
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macrophages using Trizol reagent (Thermo Fisher) were subjected to RT-PCR to assess
mRNA expression using the following primers: IL-1beta-Fwd; 5’-ATGGCAACTGTTCCTG3’,

IL-1beta-Rev;

5’-TTAGGAAGACACGGAT-3’,

TNF-alpha-Fwd;

5’-

ATGAGCACAGAAAGCA-3’, TNF-alpha-Rev; 5’-TCACAGAGCAATGACT-3’, IL-10-Fwd;
5’-ATGCCTGGCTCAGCAC-3’, IL-10-Rev; 5’-TTAGCTTTTCATTTTG-3’, GAPDH-Fwd;
5’-ATGCTGCCCTTACCCCGG-3’, and GAPDH-Rev; 5’-TTACTCCTTGGAGGCCAT-3’.

4.3.9 Macrophage cellular uptake assay
LPS-stimulated, CeONP-treated macrophages were washed in PBS and collected
by scraping and centrifuging at 160 rcf for 5 minutes. The cells collected in a pellet were
then fixed in a solution that contained 2.5 % glutaraldehyde and 2 % formaldehyde. The
fixed cell pellet was cut into thin sections (~ 60 nm), stained, and placed on copper grids
for TEM analysis.

4.3.10 Western Blotting Analysis
For Western blotting, proteins were resolved by SDS-PAGE and transferred onto
0.45μm PVDF membranes (Millipore). Membranes were blocked overnight at 4˚C with 5%
milk in PBS and 0.5% Tween-20 (PBST). Membranes were incubated for 60 mins with
one of the following antibodies: rat monoclonal anti-CD68 (Abcam; 1:1000), rabbit
monoclonal TNFα (Cell Signaling; 1:1000), mouse monoclonal IL-1β (Thermo Fisher;
1:1000), and mouse monoclonal IL-10 (Santa Cruz; 1:1000). This was followed by 1h
incubation with horseradish peroxidase-coupled goat anti-mouse, anti-rabbit, and anti-rat
secondary antibodies (Thermo Fisher; 1:1000). Detections were performed with PierceTM
ECL Western Blotting substrate (Thermo Fisher). Signals were quantified using ImageJ.
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4.3.10 In vivo studies
All in vivo studies were performed on male C57BL/6J mice (Jackson Laboratory)
of 12 weeks in age and ~25 g in body weight. All procedures were performed in
accordance with the guidelines approved by the University of Pennsylvania Institutional
Animal Care and Use Committee.

4.3.10.1 Peripheral inflammation model induction and paw edema thickness
Using digital calipers, basal widths of both hind paws of mice were first measured
immediately before the onset of inflammation. Peripheral inflammation was induced by
injecting 20 µl of complete Freund’s adjuvant (CFA) (Sigma) subcutaneously in the central
plantar region of left hind paws (ipsilateral), as reported in a previous study.32 At 24 h postCFA, the paw thickness of the ipsilateral (injured) paw, as index of edema, was measured
shortly before the start of treatment (0 h time point). The paw thickness of the contralateral
(uninjured) paw was also measured to assess off-target effects of CFA. To assess the in
vivo immunomodulatory effects of CeONP, the mice were randomized to two groups and
were administered with either 100 µl of saline (vehicle) or CeONP (dose of 100 mg Ce/kg).
The paw thicknesses of both ipsilateral and contralateral paws of each mouse were
measured at 3, 6, 18 and 24 h post-treatment in a blinded fashion. The paw thicknesses
at each time point and the net change compared to the basal width at 0 h were compared
between vehicle injection group (n=8) and CeONP treatment group (n=7).
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4.3.10.2 Behavioral testing: thermal pain hypersensitivity
The thermal pain hypersensitivity test was performed using a heated glass-based
plantar analgesiometer (Stoelting). Before the assessment, each mouse was placed in an
individual plexiglass cubicle on a glass surface that was warmed to 30 °C daily for 1 h to
allow mice to acclimate to the environment. The baseline measurements were taken prior
to the CFA injection (-24 h) and to the treatment (0 h) with either saline (n=4) or CeONP
(n=4). A light beam was used to produce heat by creating an intense focal spot under the
paw. Paw withdrawal latency (PWL), which was defined as the time between the onset of
heat stimulus and paw withdrawal in response, was recorded at 3, 6, 18, and 24 h posttreatment. A cut-off of 20 seconds was set to prevent tissue damage. At each time point,
each mouse was tested in five sequential trials with an interval of 2-3 minutes. PWL was
measured on both ipsilateral (injured) and contralateral (uninjured) hind paws.

4.3.10.3 Biodistribution
At 24 h post-treatment, mice were sacrificed to analyze the biodistribution of
CeONP. Blood samples, major organs (i.e., heart, lungs, liver, spleen, kidneys), hind
paws, and the remaining carcass from each CeONP-treated mouse were harvested and
homogenized for tissue digestion. The concentration of cerium in the digested samples
were measured using ICP-OES. The results were analyzed by % injected dose (% ID) and
% injected dose per gram of tissue (% ID/g).
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4.3.11 Ex vivo studies
4.3.11.1 Renal clearance of CeONP
To further investigate the renal clearance of CeONP, urine samples of mice from
CeONP-treatment group were collected 3 h post-injection. The collected urine samples
were placed on copper grids for TEM analysis.

4.3.11.2 In vivo toxicity
Heart, lungs, liver, spleen, and kidneys from both vehicle and CeONP treatment
groups were collected at 24 h post-treatment for histological analysis via H&E staining.
Each tissue was sliced at thickness of 12 microns for staining.

4.3.11.3 In vivo immunomodulatory effect of CeONP
The immunomodulatory effects of CeONP in the paw inflammation model was
investigated by performing Western blotting and immunohistochemistry of several
biomarkers – CD68 (M1 macrophage), TNFα and IL-1β (pro-inflammatory cytokines) and
IL-10 (anti-inflammatory cytokine). Histological analysis via H&E staining was also
conducted. The immunomodulatory effect was assessed by comparing the results with
hind paws of wild-type (no CFA injection or treatment) and vehicle groups.

4.3.12 Statistical analysis
One-way analysis of variance (ANOVA) and Tukey-Kramer HSD posthoc test were
used to examine statistical significance in differences between the groups when there are
more than 2 groups to compare (e.g., in vitro experiments). A two-sample t-test was used
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when there are only 2 groups in comparison (e.g., in vivo experiments). Data is presented
in mean ± SD unless indicated otherwise.

4.4 Results
4.4.1 Synthesis and characterization of citric acid coated CeONP
Ultrasmall citric acid coated CeONP were synthesized via a one-step coprecipitation of cerium precursor and citric acid in ammonium hydroxide as depicted in
Figure 4.1A. As the reaction proceeded, the color of the solution became yellow. The final
solution had peak UV-vis absorbance at 265 nm (Figure 4.1B).9, 33 The citric acid coating
was used to provide hydrophilicity and stability of CeONP in physiological buffer solutions,
such as PBS (Figure 4.1C). As shown in the transmission electron micrographs (Figure
4.1D), CeONP are nearly spherical with an average core diameter of 2.8 ± 0.4 nm. The
citric acid coating on the surface led to hydrodynamic diameter that is slightly larger (3.4
± 1.1 nm) than the core diameter and negative ζ-potential (19.5 ± 3.2 mV) as shown in
Figure 4.1E. The elemental composition of CeONP was analyzed with further
characterization methods with energy-dispersive X-ray spectroscopy (EDX), X-ray
diffraction analysis (XRD) and Fourier transform infrared spectroscopy (FT-IR). EDX
verified that the main elemental components of the core nanoparticles are cerium and
oxygen (Figure 4.1F), and the XRD diffraction pattern confirmed a fluorite lattice structure
of CeONP highlighted by a strong (111) peak (Figure 4.1G).34 Similarities in FT-IR spectra
of citric acid powder and citric acid coated CeONP demonstrated that the surface coating
of citric acid molecules was intact (Figure 4.1H). Notably, the characteristic peak of C=O
vibration at 1701 cm-1 from the carboxylic acid group of citric acid was shifted to 1579 cm1

in citric acid coated CeONP, indicating successful bindings of citric acid molecules onto
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the nanoparticle surfaces.35 The peak at 1396 cm-1 from the bending of tertiary hydroxyl
group of citric acid was also observed in both FTIR spectra.36

Figure 4.1 Characterization of citric acid coated CeONP.
A) Schematic depiction of CeONP synthesis. B) UV-vis spectrum, C) hydrodynamic
diameters in water and PBS, D) micrograph from TEM, E) core and hydrodynamic
diameters and surface charge, F) EDX spectrum, and G) XRD pattern of CeONP. H) FTIR
spectra of citric acid and CeONP.

4.4.2 In vitro cytocompatibility
To evaluate the feasibility of using CeONP for biomedical applications, the safety
and cytotoxicity of CeONP were first examined by assessing the viability of endothelial
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cells, hepatocytes, kidney epithelial cells and macrophages upon CeONP treatment.
These cell types will likely have the highest exposure and accumulation once CeONP
have entered the systemic circulation in vivo. 24 h of CeONP treatment did not
substantially decrease the viability of any of the cell types in this study even at high dose
of 2.5 mg Ce/ml (Figure 4.2). The lowest viability observed was 98.5 ± 1% in hepatocytes
that were treated at concentration of 2.5 mg Ce/ml. The lack of substantial reduction in
cell viability demonstrates the excellent cytocompatibility of the CeONP formulation. As
the cytotoxicities of nanoparticles are largely affected by their physiochemical properties,
the biocompatible and stable citrate coating likely prevented induction of toxic effects to
these cells. Furthermore, we expect the actual exposure of these cells to CeONP to be
much lower in both concentration and time than the parameters used in this experiment
due to efficient renal excretion.

Figure 4.2 In vitro cytotoxicity of citric acid coated CeONP.
Cell viability of HepG2, Renca, SVEC4-10 and RAW264.7 after 24 h of CeONP treatment
normalized to no treatment group. *p < 0.05.
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4.4.3 In vitro contrast generation
The potential to detect CeONP in CT imaging was investigated by assessing the
CT contrast properties of CeONP in an in vitro phantom study using a SOMATOM Force
clinical CT scanner. The attenuation rates of CeONP were compared to those of cerium
precursor, AuNP (a leading experimental CT contrast agent) and iodinated contrast agent
(iopamidol). A strong linear correlation (R2 > 0.997) between the attenuation values and
the cerium concentrations was observed (Figure 4.3A). The attenuation rate of CeONP
was the highest at 80 kVp and steadily declined with increasing tube voltages (Figure
4.3B). The decline is due to cerium’s K-edge energy of 40.4 keV, at which the number of
photons at the energy level is the highest when scanned at 80 kVp, followed by 100 kVp,
120 kVp and 140 kVp, respectively. Despite the decline, CeONP had consistently higher
attenuation rate over that of iopamidol, a commonly used CT contrast agent, across all
tube potentials tested. The attenuation of CeONP was also much higher than that of AuNP
in 80, 100, 120 kVp, demonstrating the potential advantages of using cerium-based
nanoparticles for contrast-enhanced CT imaging. However, relatively low elemental
density of cerium and of cerium payload in CeONP can limit their use for certain imaging
applications, in which high payload delivery may be required.

Figure 4.3 In vitro contrast generation of CeONP in clinical CT imaging.
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A) Attenuation of CeONP at a range of concentrations. B) Attenuation rates of CeONP
compared to cerium precursor salt, iopamidol and AuNP. (n.s. = not significant or p > 0.05,
*** = p ≤ 0.001 compared to CeONP).

4.4.4 Enzyme-mimetic antioxidative activities
An array of antioxidant enzymes is present in the body to protect cells from
oxidative stress.4 The main examples of such enzymes are SOD and catalase, which help
break down two predominant forms of cell-derived ROS, superoxide and hydrogen
peroxide, into oxygen and water molecules.37 The SOD-mimetic and catalase-mimetic
activities of CeONP were investigated to determine whether their citric acid coating
allowed catalysis to occur. A dose-dependent increase in SOD-mimetic activity was
observed, demonstrating effective removal of superoxide ions by CeONP (Figure 4.4A).
Similarly, high levels of catalase-mimetic activities of CeONP were observed in a dosedependent manner, where the conversion rate plateaued at 0.05 mg/ml (Figure 4.4B).
These results demonstrate the ability of citric acid coated CeONP to efficiently catalyze
the conversion of superoxide anion to hydrogen peroxide, as well as of hydrogen peroxide
to oxygen and water molecules.

Figure 4.4 ROS scavenging activities of CeONP.
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Scavenging efficiency of CeONP against A) superoxide ion and B) hydrogen peroxide.

4.4.5 In vitro ROS and RNS scavenging activities
The reactive oxygen species scavenging activities of CeONP were further
demonstrated in a cellular environment by examining the intracellular ROS and NO
production levels in LPS-stimulated macrophages. ROS and other inflammatory
mediators, such as NO, are vigorously produced in macrophages upon LPS stimulation
through activation of TLR4 and NADPH oxidase.38-40 The intracellular ROS levels were
evaluated using an ROS-sensitive dye, DCFH-DA, that forms a fluorescent compound
once it is oxidized after being cleaved by intracellular esterases. As shown in Figure 4.5B,
LPS stimulation caused a significant elevation in intracellular ROS level, and CeONP
treatment resulted in marked suppression of intracellular ROS levels in the LPS-stimulated
macrophages. The reduction was significant even at the lowest treatment concentration
of 0.01 mg or 10 µg Ce/ml. TEM analysis of CeONP-treated, LPS-stimulated macrophages
revealed active cellular uptake of CeONP at both low (0.05 mg Ce/ml) and high (0.5 mg
Ce/ml) treatment concentrations (Figure 4.5A), implying that CeONP can scavenge
intracellular ROS by directly interacting with ROS molecules in the cellular compartments.
The suppression of intracellular ROS levels also demonstrates that ROS-scavenging
activity of CeONP is preserved in a cellular environment, specifically of macrophages.
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Figure 4.5 Reactive species scavenging activity of CeONP in macrophages.
A) TEM of CeONP-treated macrophages at concentrations of 0.05 mg/ml (left) and 0.5
mg/ml (right). B) Intracellular ROS levels and C) RNS production levels in control and LPSstimulated macrophages upon CeONP treatment. *** p < 0.001.

Another well-established inflammatory mediator is RNS, namely nitric oxide
(NO).41 Overproduction of NO by macrophages in response to inflammatory stimuli can
cause damage to healthy tissues through both macrophage-mediated cytotoxicity and
formation of peroxynitrite via interaction with other ROS in the environment.42 Therefore,
inhibition of NO production in macrophages was also examined. Similar to intracellular
ROS production, LPS stimulation of macrophages significantly elevated NO production
when compared to the unstimulated cells (Figure 4.5C). Subsequent CeONP treatment
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notably decreased the NO production in a dose-dependent manner. NO production was
significantly lowered even at the lowest treatment concentration tested (0.01 mg Ce/ml).

4.4.6 In vitro anti-inflammatory effect
Previous studies have shown that both ROS and RNS can regulate LPS-induced
signal transduction in phagocytic immune cells, predominantly in macrophages, to induce
secretion of proinflammatory cytokines, namely IL-1β and TNFα.5,

39, 43

To examine

whether ROS and RNS scavenging activities of CeONP in activated macrophages can
translate to suppression of proinflammatory cytokine secretion, we assessed the mRNA
expression and cytokine secretion of TNFα and IL-1β upon CeONP treatment.
LPS-induced activation of macrophages elevated mRNA expression of TNFα by
more than 6-fold (Figure 4.6A) and was abated by

CeONP treatment. While the

downregulation was gradual at lower doses of CeONP, it was significant at higher doses
(i.e., 0.5 and 1 mg Ce/ml) when compared to non-treated macrophages. A similar pattern
of inhibition was observed in IL-1β – minor decline at lower dose treatment and significant
reduction at higher doses (Fig 5.6B). Interestingly, CeONP treatment reduced the cytokine
secretion of both TNFα and IL-1β much more robustly than it did for their mRNA
expression, significantly repressing the secretion at 0.01 mg/ml for TNFα and 0.1 mg/ml
for IL-1β (Fig 5.6D and E).
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Figure 4.6 In vitro anti-inflammatory effect of CeONP in LPS-stimulated macrophage cells.
mRNA expression levels of A) TNFα, B) IL-1β and C) both in gel image normalized to
GAPDH. Cytokine secretion of D) TNFα and E) IL-1β. n.s. not significant, **p < 0.01, ***p
< 0.001.

We also investigated the secretion of IL-10 in macrophages upon CeONP
treatment. IL-10 is a cytokine with potent anti-inflammatory properties that is known to
inhibit expression of proinflammatory cytokines, such as TNFα, IL-1β, and IL-6, and to
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eliminate dysfunctional mitochondria that generate excessive amounts of ROS.44 LPSstimulation resulted in a slight increase in mRNA expression of IL-10 (Figure 4.7A and B).
Upon CeONP treatment, mRNA expression of IL-10 was continuously elevated in a dosedependent manner. A similar pattern of upregulation was observed in cytokine secretion
as well. However, the level of secretion declined when the cells were treated with CeONP
concentration higher than 0.1 mg/ml (Figure 4.7C).

Figure 4.7 IL-10 expression of LPS-stimulated RAW 264.7 cells.
A) mRNA expression level, B) corresponding gel electrophoresis image, and C) cytokine
release level of IL-10 in LPS-stimulated RAW 264.7 cells.

4.4.7 In vivo immunomodulatory effect
Paw edema reduction. To evaluate the immunomodulatory effect of CeONP in vivo, we
studied whether CeONP can reduce edema and decrease pain hypersensitivity in mice
that suffer from acute hind paw inflammation. CFA injections directly in the left paws of
mice induced local inflammation, causing noticeable redness and swelling that
significantly increased the paw thickness (Figure 4.8).
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Figure 4.8 Images of inflamed paws of vehicle injected and CeONP treated mice over 24
h period.

After a single dose injection of CeONP via the tail vein, the edema in the left paw
was quickly alleviated, as shown by a rapid decline in paw thickness over the 24 h postinjection period, demonstrating the efficacy of CeONP in modulation of acute inflammatory
response. (Figure 4.9A). Vehicle (saline) injection, on the other hand, did not cause any
significant reduction in paw thickness. When comparing the changes in paw thickness
between CeONP-treated and vehicle-injected groups over the monitored time, a
significant difference was observed as early as 6 h post-injection, and the difference
continued to grow over the next 18 h. No significant change in contralateral paw thickness
and body weight was observed in both treatment groups during the monitoring (Figure
4.10).

132

Figure 4.9 In vivo edema reduction and suppression of proinflammatory cytokines and
macrophage recruitment in acute hind paw inflammation.
A) Change in paw thickness over 24 h post-injection period in comparison to immediately
before the treatment (0 h). B) H&E staining of acute inflammation site from wild type,
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vehicle and CeONP treatment group. Scale bar = 50 µm. C) Western blot analysis of
TNFα, IL-1β and CD68 in inflamed paws of each group. No inflammation was induced in
wild-type mice. Data presented as mean ± SEM. * p < 0.05, **p < 0.01, ***p < 0.001.

Figure 4.10 Off-site effect of CeONP treatment.
A) Paw thickness of contralateral paws (no inflammation induction via CFA injection). B)
body weight of mice during CFA injection and CeONP treatment.

Reduction in macrophage recruitment and proinflammatory cytokine expression.
The modulation of acute inflammation in the paw was further examined via histologic
analyses and western blotting. H&E staining of inflamed paws of mice that were injected
with saline clearly showed histopathologic alterations and elevated cell density in the
region when compared to the paws of the wild-type mice (no CFA injection), suggesting
damage related to inflammatory cell infiltration (Figure 4.9B). Both alteration and cell
density were significantly reduced in mice that were treated with CeONP, indicating
lessening degree of inflammatory response within 24 h. Western blot analyses of proinflammatory cytokines (i.e., TNFα and IL-1β) and a macrophage biomarker (i.e.,CD68)
also showed elevated levels of all three markers in inflamed paws of vehicle injected mice
compared to those of wild-type counterparts (Figure 4.9C). 24 h after CeONP treatment
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markedly reduced the cytokine expression and CD68 levels when compared to the vehicle
group. Reduction in CD68 implies that the reduction in cell density is possibly due to
abatement in macrophage cell recruitment and infiltration to the inflammation site. Western
blotting further showed that the immunomodulation in CeONP-treated group was also
influenced by increased IL-10 expression (Figure 4.11).

Figure 4.11 In vivo IL-10 expression in mice.
Western blot analysis of IL-10 in inflamed paws of each treatment group. No inflammation
induction in WT.

Suppression in pro-inflammatory cytokines and macrophage recruitment and
upregulation

of

an

anti-inflammatory

cytokine

were

further

investigated

by

immunofluorescence staining. As shown in Figure 4.12, secretion of both TNFα and IL-1β
at the inflammation site were much lower in CeONP-treated group than saline group. The
recruitment of CD68-positive macrophages to the inflamed region was also less in the
CeONP treatment group. The yellow areas in the merged images where the cytokines and
CD68 markers are co-localized indicate that significant amounts of TNFα and IL-1β were
secreted by CD68-positive macrophages. Staining of IL-10 anti-inflammatory cytokine
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also revealed that CeONP treatment promoted higher IL-10 expression at the
inflammation site (Figure 4.13). Strong fluorescence signals of IL-10 were also detected
in areas where CD68 markers were not prominent, indicating the possibility of upregulation
of IL-10 expression by other immune cells, namely regulatory T cells.
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Figure 4.12 Immunofluorescence analysis of pro-inflammatory cytokines and a
macrophage marker.
Immunofluorescence images of CD68 and DAPI markers in paw tissues merged with A)
TNFα and B) IL-1β markers. Scale bar = 200 µm.

Figure 4.13 Immunofluorescence analysis of IL-10 and a macrophage marker.
Immunofluorescence staining of CD68 and DAPI markers in paw tissues merged with IL10 marker. Scale bar = 200 µm.

In vivo analgesic effect. CeONP treatment also resulted in significantly reduced pain
hypersensitivity, measured by the increase in PWL (paw withdrawal latency defined by the
time between the onset of heat stimulus and paw withdrawal in response), when compared
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to the saline group over the 24 h of post-injection monitoring (Figure 4.14). A significant
difference between the two groups was observed as early as 3 h post-injection, which was
the earliest time point. The PWL of CeONP-treated mice at 3 h post-injection was also
significantly higher than PWL immediately before the treatment (0 h timepoint), indicating
fast-acting analgesic effect of CeONP . Furthermore, the PWL of CeONP-treated mice at
18 h became comparable to that of before the CFA injection (-24 h timepoint), further
indicating that CeONP can alleviate pain hypersensitivity.

Figure 4.14 Thermal pain hypersensitivity in the hind paw acute inflammation.
PWL of individual mouse injected with vehicle and CeONP over 24 h post-injection. Data
presented as mean ± SEM. * p < 0.05, **p < 0.01, ***p < 0.001.

4.4.8 Biodistribution and renal clearance
The biodistribution of CeONP was also investigated in the acute paw inflammation
mouse model at 24 h post-injection to examine the efficacy of CeONP clearance and to
analyze the accumulation of CeONP at the inflamed paw. ICP-OES analysis demonstrated
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that less than 16 %ID was found in the body at 24 hours post-injection (Figure 4.15A).
This suggests that more than 84 %ID was excreted from the body via urine and feces.
Micrographs from TEM of CeONP found in urine samples collected at 2 h post-injection
further support efficient excretion (Figure 4.15C). The average retention of ~16 %ID is
comparable or lower than other reports of renally clearable nanoparticles.29, 45, 46 Such low
retention can be explained by the low hydrodynamic size of CeONP, which is considerably
lower than the widely accepted size threshold for renal clearance (i.e., ~ 5.5 nm) and their
favorable surface chemistry.30, 47 Most of the CeONP retention were observed in liver and
spleen. Small amounts of CeONP were also found in kidney (0.7 %ID, 1.6 %ID/g), lungs
(0.3 %ID, 0.7 %ID/g), and the remaining carcass (1.2 %ID, 0.0 %ID/g). A considerable
amount of CeONP was also found in the inflamed paw, which was about 10-fold higher
than that of contralateral paw without inflammation (Figure 4.15B). The significantly higher
accumulation in the inflamed paw can be explained by enhanced permeability and
retention effect due to increased vascular permeability of the capillaries at the
inflammation site.48
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Figure 4.15 Biodistribution and renal clearance of CeONP.
A) Accumulation of CeONP in the major organs and the remaining carcass and B)
ipsilateral and contralateral paws of mice at 24 h post-injection as measured by ICP-OES.
C) TEM of urine samples from CeONP-treated mice collected at 2 h post-injection.

4.4.9 In vivo toxicity
Our in vivo results thus far demonstrated that CeONP can have beneficial effects
at the inflammation site and be effectively cleared from the body within 24 hours; however,
it is still unclear whether they have toxic effects in other major organs (e.g., heart, lung,
liver, spleen, and kidney) as a portion of the dose was retained at this time point.
Therefore, the major organs were harvested at the end of the in vivo studies for histological
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analysis. H&E staining of these organs revealed no noticeable acute pathological toxicity
or adverse effects in both control (saline) and CeONP-treated groups (Figure 4.16).

Figure 4.16 In vivo safety of citric acid coated CeONP.
Micrographs of H&E stained major organs (heart, lung, liver, spleen, and kidney) from
mice 24 h after injection with saline (control) or CeONP at 100 mg/kg. Scale bar = 50 µm.

4.5 Discussion
Nanoparticle characterization demonstrated stable CeONP with unimpaired citric
acid surface coating. Similarly to magnetite nanoparticles, citric acid coating on CeONP
surfaces provided electrostatic and steric stability to allow CeONP to retain its ultrasmall
nanoparticle size and water solubility.49 These physical and chemical properties are of
importance to promote renal clearance while maintaining its immunomodulatory
properties. The citric acid surface coating also did not interfere with the nanoparticles’
ability to efficiently catalyze the conversion of superoxide anion to hydrogen peroxide, as
well as of hydrogen peroxide to oxygen and water molecules.
CeONP’s catalytic activity was extensively tested in macrophages, since they are
specialized in elimination of pathogens by producing an excessive amount of reactive
species.4 More studies are suggesting that ROS have a close relationship in activating
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macrophage cells by directly promoting expression of proinflammatory genes and
polarization of macrophages to proinflammatory M1.1, 50 While M1 macrophages function
in uptake and clearance of apoptotic cells, their excessive and prolonged ROS and RNS
production can cause collateral damage to healthy tissue and may even be harmful to
macrophages themselves. Therefore, modulation of macrophage activation can be of
promising therapeutic focus in inflammatory diseases. Our findings suggest that CeONP
can prevent excessive production of ROS and NO in macrophages; therefore, can
potentially modulate inflammatory responses and alleviate tissue damage from activated
macrophages at the inflammation site.
In fact, our in vitro and in vivo results indicate that CeONP with strong antioxidant
properties can have potent anti-inflammatory effect in activated macrophages,
downregulating proinflammatory cytokines, TNFα and IL-1β, and upregulating antiinflammatory cytokine, IL-10. The suppression of secretion of TNFα and IL-1β were
sustained at higher CeONP doses, whereas IL-10 expression declined at the highest
doses. It suggests there may be an optimal dose of CeONP that can yield the most
effective immunomodulation of activated macrophages, which is supported by the findings
of previous studies.25, 51 It also implies that CeONP can reduce macrophage polarization
towards M1-like macrophages, which can secrete both excessive amounts of reactive
species and pro-inflammatory cytokines, and promote polarization towards M2-like
macrophages, which can regulate inflammation and promote wound healing by secreting
anti-inflammatory cytokine.52
In our animal model, we initially observed a significant elevation in TNFα and IL1β secretion in the inflamed paw from CFA injection, as previously demonstrated.32 Mainly
produced by macrophages, these pro-inflammatory cytokines are key participants in the
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increase in vessel permeability, edema formation and oxidative stress at the inflammation
site.53 Our results suggest that CeONP can alleviate these key processes in acute
inflammatory response via suppression of the pro-inflammatory cytokines. Another
important development in acute inflammation is rapid recruitment of circulating monocytes,
which is well-known to be facilitated by ROS.54 Activation of these recruited monocytes
transforms them into CD68-positive macrophages, which contribute to the inflammatory
responses via removal of apoptotic cells.55 However, excessive activation of the
macrophages at the inflammation site can cause collateral damage to healthy tissue,
necrosis and fibrosis. Since the phagocytic activity of macrophages is significantly affected
by mitochondrial or intracellular ROS, ROS scavenging activities of CeONP can have
therapeutic benefits in decreasing lesion development by moderating pro-inflammatory
cytokine secretion and reducing macrophage recruitment.56 Modulation of proinflammatory cytokines also can lead to the alleviation in pain hypersensitivity, as both
ROS and pro-inflammatory cytokines are known to be involved in the process of
pathological pain.57
In assessment of the safety of CeONP, effective renal clearance and
biocompatible surface coating of CeONP led to no detection of any adverse effects as
demonstrated by histological analyses and observation of stable body weight. Rapid and
efficient renal clearance of CeONP can also reduce long-term cytotoxicity concern and
increase the translational potential of the nanoparticle formulation. The importance of size,
surface chemistry, coating integrity in nanoparticle toxicity is emphasized as nanoparticle
toxicity is heavily dependent on its physiochemical properties.58 Our findings suggest that
citric acid coated CeONP can be biocompatible and highly tolerable even at a high
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injection dose (100 mg/kg). However, more extensive studies are needed in future to
further prove their clearance and safety, as is standard for approval of a new agent.
While the clearance of CeONP has been demonstrated in this study, more
extensive studies on the safety and clearance of our nanoparticles will need to be
performed, such as at multiple timepoints out to a month or longer and in larger animal
models than mice. Monitoring of organ functions via blood markers (e.g., AST and ALT
blood levels for liver function assessment), especially for the liver where we observed the
highest nanoparticle accumulation will need to be further examined for a prolonged period
of time. Treatment dose is another important parameter to consider in evaluating the
safety of CeONP. Previous reports of CeONP formulations with poor particle stability and
renal clearance have shown that they can cause organ damages when injected at high
doses.59,

60

Although the rapid clearance and stable coating integrity of our CeONP

formulation resulted in no noticeable toxicity issues from the treatment, optimal dose
regimen and administration route can further improve the safety profile while preserving
the immunomodulatory effects in acute inflammation. It is also expected that potential
adverse effects from ROS scavenging activities in non-target areas will be minimal as their
catalytic activity is limited by the low oxygen concentration inside our body, scavenging
free radicals only when they are elevated.51 Furthermore, significant amounts of CeONP
accumulated at the inflammation site despite the lack of active targeting moieties,.
The close connection between oxidative stress and inflammation has led to
numerous studies that also have reported immunomodulatory effects of nanozymes in
treatment of inflammatory diseases.61, 62 The potent modulation of immune response in
acute inflammation shown in our study also encourages the use of CeONP for treatment
of diseases affected by chronic inflammation, such as autoimmune diseases, rheumatoid
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arthritis, chronic open wounds, and atherosclerosis. For effective management of such
diseases, the timing of CeONP therapy is expected to be vital in addition to dose and
administration route. The efficacy of antioxidant treatment in the onset and the advanced
forms of chronic inflammation will also need to be investigated.
Apart from therapeutic efficacy and safety profile of citric acid coated CeONP, our
phantom imaging results suggest that CeONP can be promising CT contrast agents that
can generate higher CT contrast than iodinated contrast agents in all tube potential
settings. CeONP also produced higher CT attenuation when compared to gold
nanoparticles in lower tube potential settings, ranging from 80 to 120 kvP. Combined with
their ability to accumulate at the inflammation site, CeONP can potentially be used for
target imaging of inflammatory diseases.

4.6 Conclusion
In this study, we synthesized ultrasmall CeONP with strong antioxidant properties
that can be used for immunomodulation of inflammatory response. These nanoparticles
were efficient in ROS scavenging and suppression of inflammatory cytokine secretion in
macrophages in vitro, which translated to reduction in edema, suppression of macrophage
recruitment and alleviation of pain hypersensitivity in vivo. They were also biocompatible
and showed rapid excretion from the body to reduce the long-tern toxicity concern. Our
findings demonstrate that CeONP are highly promising material for effective modulation
of immune response with higher potential for clinical translation.
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CHAPTER 5: LABELING SOLID TUMOR TARGETING CAR-T CELLS
FOR CT AND SPCCT CELL TRACKING IN CANCER IMMUNOTHERAPY
5.1 Abstract
The clinical success of FDA-approved CAR-T cell therapies against hematologic
malignancies has created substantial interest in further improving their safety and efficacy
as well as in developing new CAR-T cell therapies for solid tumor treatment. While there
have been some promising results, most clinical trials to date report severe toxicities, poor
tumor specificity and limited persistence. A method that can directly monitor the
administered CAR-T cells can greatly facilitate the development of new CAR-T cell
therapies by providing information on cell biodistribution and persistence. In this study, we
labeled primary human CAR-T cells with gold nanoparticles (AuNP) to allow monitoring of
the CAR-T cells with both CT and photon-counting CT (SPCCT) imaging. We found that
our labeling method that utilizes a commercially available transfection reagent can
promote sufficient internalization of AuNP by CAR-T cells without significantly affecting
their viability and main cellular functions. We also demonstrate that the cellular uptake of
AuNP by CAR-T cells was sufficient to visualize the labeled cells in both CT and SPCCT
imaging.
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5.2 Introduction
Chimeric antigen receptor (CAR)-T cell therapy has resulted in unprecedented
clinical responses in patients with certain forms of hematologic malignancies.1, 2 Recent
FDA approvals of CD19-targeting CAR-T cells and their subsequent clinical successes
have motivated a plethora of studies to develop CAR-T cell therapies with improved
efficacy and safety. One of the main directions of these CAR-T cell therapies is to develop
them for solid tumor treatment. Numerous approaches are under clinical investigation to
achieve this, such as new CAR designs and the use of new tumor antigens.3-6 The safety
and feasibility of these innovative CAR-T cell therapies are being demonstrated in some
studies.7-10 However, despite the recent advances, solid tumor treatment remains
challenging as solid tumors present additional hurdles, such as lack of antigens that are
truly tumor-specific and immunosuppressive tumor microenvironments. To develop CART cell therapies with desirable therapeutic efficacy and safety, many aspects of CAR-T
cells, such as their trafficking, persistence, and target tumor specificity, need to be closely
examined. However, these vital parameters, especially the full extent of CAR-T cell
biodistribution, are often poorly understood, and conventional monitoring methods from
biopsies and biomarker analyses only provide indirect information on such parameters.
Therefore, a reliable method to track and monitor infused CAR-T cells in vivo will provide
invaluable insights and facilitate the progression of CAR-T cell therapy in solid tumor
treatment.
X-ray computed tomography (CT) could be used to track labeled CAR-T cells in a
non-invasive and real-time manner. Our group has previously demonstrated the feasibility
of monitoring the recruitment of monocytes that are labeled with gold nanoparticles (AuNP)
to atherosclerotic plaques with CT imaging.11 Furthermore, we have recently
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demonstrated for the first time that spectral photon-counting CT (SPCCT), a new CT
technology under clinical development, can specifically detect macrophages labeled with
AuNP in vivo.12 The AuNP signals from the SPCCT system were also linearly correlated
with AuNP biodistribution determined by analytical tools, allowing accurate quantification
of the AuNP labels, and therefore, the number of localized cells.13, 14 Moreover, we also
found that SPCCT can detect AuNP accumulation in the bone marrow,13 which serves as
a marker of the persistence in patient response to CAR-T cell therapies. All of these
features are highly attractive in CAR-T cell monitoring, allowing specific visualization of
the labeled cells and analyses of biodistribution and patient response at multiple time
points without tumor resection.
Herein, we develop a labeling method to track CAR-T cells with both CT and
SPCCT imaging in an effort to facilitate the advancement of novel CAR-T cell therapy for
solid tumor treatment with better monitoring of infused cell behaviors. We demonstrate
that small AuNP encapsulated in lipid-based transfection reagent can be used for labeling
CAR-T cells without significant effects on the cell viability and functions and can allow
visualization of the labeled CAR-T cells in CT and SPCCT imaging.

5.3 Materials and methods
5.3.1 Materials
Gold(III) chloride trihydrate (>99.9% trace metals basis) was purchased from
Sigma-Aldrich (St. Lous, MO). Lipofectamine 2000 ransfection reagent, human T-activator
CD3/CD28 Dynabeads, LIVE/DEAD assay kits were acquired from Life Technologies
(Grand Island, NY). Primary human CAR-T cells were a gift from Avery Posey’s lab at the
University of Pennsylvania.
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5.3.2 Gold nanoparticle transfection agent synthesis
Glutathione-coated, sub-5 nm AuNP were synthesized by the same method used
in Chapter 3. Briefly, gold(III) chloride salt in water was reduced by dropwise addition of
sodium borohydride solution, and 10 mg of glutathione was subsequently added to the
solution after 30 minutes. The resulting solution was washed in deionized water by
centrifugation in molecular cut-off centrifugation tubes. Immediately before labeling the
cells, AuNP of desired concentration was mixed with lipofectamine (mass ratio of 6:1).

5.3.3 Nanoparticle characterization
Transmission electron microscopy (TEM) was used to determine the core sizes
and morphologies of glutathione-coated small AuNP and lipofectamine-encapsulated
AuNP. The images were acquired using a Tecnai T12 microscope (FEI, Hillsboro, OR) or
a JEOL 1010 microscope (JEOL Ltd., Japan).

5.3.4 CAR-T cell culture and labeling
Primary human CAR-T cells were cultured in RPMI media supplemented with 30
U/ml of IL-2. After thawing, the cells were allowed to be activated by adding CD3/CD28
Dynabeads in 1:1 bead-to-cell ratio. The activated cells were expanded by adding extra
volume of media to maintain the cell density at 1 x 106 cells/ml. To label the cells, AuNP
that were encapsulated by lipofectamine was added to CAR-T cells (2 x 106 cells in 6-well
plate) immediately after the mixing step in section 4.3.2.
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5.3.5 Cellular uptake
The amounts of internalized AuNP in CAR-T cells were assessed by collecting
labeled CAR-T cells and performing ICP-OES analysis. CAR-T cells were collected in a
pellet by centrifuging at 160 x g for 5 minutes. The cell pellet was then digested in aqua
regia for gold measurement by ICP-OES.

5.3.6 In vitro viability and CAR-T cell function assays
The LIVE/DEAD assay was performed using the same method described in earlier
chapters. Tumor cytotoxicity and cytokine production of Jurkat E6-1 cell targeting 5E5
CAR-T cells were tested before and after AuNP labeling. For cytotoxicity assays, 1 x 105
tumor cells were seeded in 48-well plates, and after 24 hours, different amounts of CART cells were added (effector/target ratio ranging from 0.25 to 3:1). For cytokine production
assays, supernatants were collected 24 hours after the co-culture to analyze the
production levels of CD107a, TNFα, IL-2, BzmB and IFNγ using the human cytokine 30plex panel on the Luminex system (Thermo Fisher Scientific) and DuoSet ELISA
Development Kit (R&D Systems).15 For both assays, CD19 targeting CAR-T cells were
used as a control.

5.3.7 CT and SPCCT phantom imaging of labeled CAR-T cells
AuNP-labeled CAR-T cells were collected as pellets at the bottom of 1.5 ml
microcentrifuge tubes for in vitro phantom imaging in a SOMATOM Force clinical CT
system (Siemens Healthineers, Germany) and a MARS-12 v.5 commercially-available
preclinical spectral CT system (MARS Bioimaging Ltd., New Zealand) located at the
University of Notre Dame.
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5.4 Results
5.4.1 CAR-T cell transfecting gold nanoparticle synthesis and characterization
Small AuNP were synthesized and capped with glutathione that can provide
stability in biological fluids and render negative surface potential to allow facile
encapsulation in the lipofectamine transfection reagent, which consists of cationic lipids
that can form liposomes and other lipid-based structures. As shown in Figure 5.1A,
glutathione-capped small AuNP were uniform in size and spherical in morphologies. Upon
mixing with lipofectamine in hydrophilic conditions, AuNP were successfully complexed
with the transfection reagent to form large lipid-coated structures (Figure 5.1B).

Figure 5.1 Morphologies of small AuNP and lipofectamine-encapsulated AuNP.
TEM of A) small AuNP and B) AuNP encapsulated in lipofectamine transfection reagent.

5.4.2 Selection of CAR-T cell labeling conditions
We treated CAR-T cells with lipofectamine-coated AuNP to label the cells. We
assessed both viability and AuNP uptake by CAR-T cells after treating the cells with a
range of concentrations (0.05, 0.1 and 0.25 mg Au/ml) and duration (1, 8, 24 hours) to
161

select a treatment condition that yields the highest cellular uptake without significant
disruption in CAR-T cell viability. As shown in Figure 5.2A, the cellular uptake of AuNP
were heavily dependent on AuNP treatment concentration, resulting in higher cellular
uptake with increasing treatment concentration. The treatment duration did not noticeably
affect the uptake; however, it greatly affected the CAR-T cell viability. At 1 hr of treatment,
cell viability was not reduced significantly when compared to the control (no AuNP
treatment) across all treatment concentrations (Figure 5.2B). Numbers of viable CAR-T
cells started to diminish at longer treatment times, resulting in a significant reduction in
viability in treatment concentrations of 0.1 and 0.25 mg Au/ml at 24 hr of treatment. With
both AuNP uptake and cell viability in consideration, we decided that the best treatment
condition for our primary human CAR-T cells is the treatment concentration of 0.25 mg
Au/ml and duration of 1 hour. We used this labeling condition for further studies.
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Figure 5.2 Labeling of AuNP and its effect in CAR-T cell viability
A) AuNP uptake by CAR-T cells at varying treatment concentrations and durations. B) In
vitro cell viability of AuNP-labeled CAR-T cells. C) TEM of AuNP-labeled CAR-T cells.
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5.4.3 In vitro cellular functions
To confirm that the AuNP labeling conditions do not affect the main CAR-T cell
functions in cancer immunotherapy, we assessed the cells’ cytotoxicity against their target
tumor cells and inflammatory cytokine production. As shown in Figure 5.3A, both labeled
and unlabeled Jurkat E6-1 cell targeting 5E5 CAR-T cells had nearly 100 % tumor lysis
level across all effector to target cell ratios. Moreover, both labeled and unlabeled CD19targeting CAR-T cells did not actively bind to Jurkat E6-1 CAR-T cells had low lytic effects.
AuNP labeling also did not affect the cytokine production of 5E5 CAR-T cells,
demonstrated by similar cytokine production profiles of important cytokines, such as TNFα
and IL-2, between labeled and unlabeled cells (Figure 5.3B).

Figure 5.3 Cellular functions of labeled CAR-T cells
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Effect of AuNP labeling on the A) cytotoxicity of CAR-T cells against target tumor cells
and B) cytokine production.

5.4.4 In vitro CT and SPCCT phantom imaging of labeled CAR-T cells
We assessed CT contrast production of labeled cell pellets in CT imaging and
material differentiation in SPCCT imaging to ensure that CAR-T cells were labeled with
sufficient amount of gold payload to allow visualization in CT- and SPCCT-based cell
tracking. CT imaging of CAR-T cells labeled with 0.25 mg/ml of AuNP for 1 hour indicated
that the labeled cells can generate sufficient CT attenuation, shown by clear delineation
of the cell pellet (Figure 5.4A). The cell pellets were also scanned with a preclinical SPCCT
system, which showed high CT attenuation in conventional CT images. The sufficient CT
contrast production also led to accurate material differentiation of gold, as depicted in goldspecific K-edge images in Figure 5.4B. We could clearly distinguish the locations of AuNPlabeled pellets in the image and also quantify the amount of AuNP at the location.

Figure 5.4 In vitro phantom images of labeled CAR-T cells.
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Labeled cell pellet images from A) a clinical CT system and B) a preclinical SPCCT system
(Top left: conventional CT-like image of tubes that contain water and labeled cell pellets
from 0 and 0.1 mg/ml treatment concentration, bottom left: corresponding K-edge image,
top right: conventional CT-like image of tubes that contain labeled cell pellets from 0.25,
0.5, 1 mg/ml treatment concentration, bottom right: corresponding K-edge image)

5.5 Discussion
In cell tracking applications using CT and SPCCT imaging, it is important to
maximize the cellular uptake of the payload to overcome the relatively low sensitivity of
CT. However, such high payloads may lead to cytotoxic effects to the labeled cells. Thus,
the payload material first needs to be biocompatible and bioinert.16 As the most widely
studied experimental nanoparticles-based contrast agents for CT imaging, AuNP has
been known to have excellent biocompatibility as well as high elemental density, making
it suitable for cell tracking application. In fact, internalization of more than 100 pg of gold
per cell did not noticeably diminish the viability of CAR-T cells or alter their main cellular
functions in our study.
In addition to the payload materials, parameters used for cell labeling, such as
treatment concentration and time, also play important roles in maximizing the cellular
uptake with minimal disruption of cell viability and functions. As suggested by our results,
when using cationic transfection reagents to promote cellular uptake, short treatment
times may be ideal to label non-phagocytic cells, such as CAR-T cells, as longer treatment
times can lead to cell death. A range of treatment concentrations will also need to be
examined as overloading the cells can cause a decrease in cell viability as well. These
treatment parameters will need to be optimized for specific cell tracking applications as
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different nanoparticle formulations will be used to label different cell types. Since the
physiochemical properties of nanoparticles significantly affect the cellular interaction and
internalization, cellular uptake of the nanoparticles will vary.17 Moreover, unlike CAR-T
cells, cells that are phagocytic in nature (e.g., macrophages and neutrophils) can
internalize much higher amounts of nanoparticles and have better tolerance to the
presence of foreign materials.
The likelihood of visualizing the labeled CAR-T cells with CT and SPCCT imaging
has been demonstrated by in vitro phantom imaging in this chapter. However, further
studies are needed to confirm the feasibility of in vivo cell tracking, which depends on
numerous parameters, such as tumor size in animal models and dose and target
specificity of CAR-T cells. To maximize the potential for cell tracking, we will optimize CT
imaging parameters (e.g., energy bin threshold, reconstruction algorithm and radiation
dose) and treatment regimen (e.g., cell dose and administration route).

5.6 Conclusion
In this study, we discovered a AuNP formulation and a method to label CAR-T cells
with sufficient amount of AuNP payload to visualize the labeled cells with CT and SPCCT
imaging systems. Our labeling approach achieved this with minimal disruption in CAR-T
cell viability and their functions.
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Chapter 6: Overall discussion and future directions
6.1 Overall discussion
6.1.1 Overview
In the work presented herein, we specifically designed and synthesized various
nanoparticle formulations to develop either novel CT contrast agents that can overcome
the limitations of currently used iodinated small molecules or functional nanoparticles that
can be used to expand CT imaging applications to targeted imaging of inflammatory
diseases and cell tracking.
In chapter 2, we first screened and identified candidate elements for the
development of nanoparticle-based SPCCT-specific contrast agents. We assessed CT
contrast generation properties (i.e., attenuation and contrast-to-noise ratio) of the selected
elements and concluded that tantalum is a suitable element to develop into SPCCTspecific contrast agents. We then demonstrated the feasibility of our conclusion by
synthesizing sub-5 nm tantalum-based nanoparticles and confirming the nanoparticles’ in
vitro biocompatibility and accurate differentiation of tantalum in SPCCT imaging. We were
encouraged by our findings in tantalum’s high CT contrast production and in vitro safety
and explored its development for conventional CT contrast agents.
In examination of this idea, we hypothesized that combining tantalum-based
nanoparticles with nanoparticles made of other suitable elements, namely cerium and gold,
can lead to production of higher CT attenuation since these elements have their K-edge
energies evenly spread out in high photon flux regions of X-ray spectra used in clinical
settings. In chapter 3, we were able to successfully synthesize sub-5 nm nanoparticles
formulations, each made of cerium, tantalum, and gold, and encapsulate them in
polymeric nanoparticles of larger sizes (can be controlled to be 50 to 500 nm). In validation
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of our hypothesis, we found that the polymeric nanoparticles, or PMNP, were able to
produce consistently high CT attenuation across multiple clinical settings (i.e., tube
potential ranging from 80 to 140 kvP). In this study, we also observed that cerium
nanoparticles were able to attenuate X-ray photons much better than AuNP, especially at
low tube potentials. Concurrently, we realized that cerium has not been explored as CT
contrast agents and that CeONP are actively being investigated by researchers for their
antioxidant and potential anti-inflammatory properties at inflammation site.1-3
Thus, we developed citric acid coated CeONP for their application in CT imaging
of inflammatory diseases. In chapter 4, we examined and demonstrated their potential as
CT contrast agents as well as their capabilities to modulate inflammation. Our findings in
this study indicate that CeONP can be developed as theranostic agents for inflammatory
diseases, enabling both CT-based diagnosis and treatment of such diseases.
As established by our CeONP work, nanoparticles can be developed to have
additional functionalities to expand CT imaging applications. One CT imaging application
that our group has been actively pursuing is cell tracking. Despite high CT production of
CeONP and TaONP, both low elemental density of cerium and tantalum and the presence
of other constituents in the core of nanoparticles limit the delivery of the payload materials
into the cells of interest. For this reason, we sought to use AuNP for cell tracking of CART cells in cancer immunotherapy. As shown in chapter 5, we implemented a specific
labeling method for CAR-T cells with transfection reagent-associated AuNP to deliver high
amounts of gold payload non-phagocytic cells. In this work, we successfully demonstrated
the feasibility to promote internalization of sufficient amounts of AuNP into CAR-T cells for
CT and SPCCT imaging with minimal disruption of the cell functions in vitro. However,
more work is needed to advance this study for in vivo cell tracking.
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Here we discuss the potential of these nanoparticle contrast agents for clinical
translation and considerations to be made. We also discuss the current limitations and
strategies in expanding CT imaging application in targeted imaging and cell tracking.
6.1.2 Road to clinical translation for nanoparticle-based CT and SPCCT contrast
agents
Despite the advances in nanoparticle-based CT contrast agents, there has not
been a formulation that has been FDA approved for this application. The biggest barrier
to their clinical translation is the potential long-term toxicity from retention in the body.4 As
we did for our nanoparticle design, the most widely adapted strategy is to develop
nanoparticle formulations whose hydrodynamic diameter is less than the renal filtration
threshold of approximately 5.5 nm for rapid renal clearance from the body, minimizing or
even eliminating the retention. However, small nanoparticle size shortens the blood
circulation time, which is not ideal for CT image acquisition and localization to target sites
(e.g., tumor). This issue can be overcome by using polymers or lipids that can initially hold
the small nanoparticles together in larger-sized entities and slowly degrade over time. We
demonstrated this with PCPP polymers in PMNP formulations; however, other
biodegradable polymers, such as poly lactic-co-glycolic acid (PLGA) or chitosan, can be
explored.5, 6 Beside polymers, lipid structures (e.g., micelles and liposomes) can be formed
to pack small nanoparticles into larger nanoparticles. As an example, Higbee-Dempsey et
al. developed pH-sensitive gold-loaded polymeric micelles that can be destabilized and
release the small gold nanoparticles in acidic environments.7 With improving designs of
nanoparticle formulations and discoveries of nanoparticles made of novel heavy elements,
clinical translation of nanoparticle contrast agents for CT and SPCCT imaging seems
favorable.
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Although it still may be a long process for them to get to FDA approval, these
experimental contrast agents would especially benefit SPCCT imaging by taking
advantage of its full potential for K-edge imaging, producing higher CNR and providing
clearer material decomposition from the underlying tissue (e.g., bones). For this to happen,
more comprehensive studies will need to be completed in order to evaluate the long- term
safety of novel agents. The most promising elements for the development of SPCCTspecific contrast agents are gold, tantalum, ytterbium, bismuth, and gadolinium. Gold has
been the most extensively studied element for its use as a nanoparticle-based SPCCT
contrast agent, and its biocompatibility and high-contrast generation have already been
demonstrated in small animals. However, its high cost could limit its potential uses.
Tantalum and ytterbium both have K-edge energies near the mean photon energy
spectrum, which can lead to higher CNR production.8 The efficacy in X-ray CT imaging
and the biocompatibility of nanoparticle formulations that are based on these two elements
have also been demonstrated in several studies.9-11 However, the safety profiles of agents
based on both of these elements are still poorly understood and more comprehensive
studies are needed in order to consider clinical use. Bismuth’s high K-edge energy is
considerably greater than the mean photon energy of spectra typically used, which is a
disadvantage when considering its use as a SPCCT contrast agent. Yet, because of its
chemical inertness and affordability, it may continue to gather significant interest.
Gadolinium has been broadly studied for its delineation from other elements in phantom
imaging due to the fact that its chelates are already FDA approved for MRI. Because of
this, gadolinium chelates have potential to be used for SPCCT imaging applications as
well, although recent findings of their retention in brains and other organs raise a
concern.12
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Potentially the most attractive novel SPCCT agent for clinical translation would be
a vascular agent that is based on a higher Z element than iodine (to allow its detection via
K-edge imaging and to allow it to be distinguished from iodine agents, so that both iodine
and the novel agent can be simultaneously imaged). In addition, longer lasting vascular
contrast, such as larger nanoparticles that breaks down to smaller nanoparticles as
described earlier would address a shortcoming of the currently FDA-approved iodinated
agents, that is, very rapid blood clearance and therefore very narrow imaging window.
Nanoparticles or other types of structures in the 1-5 nm size range can also still address
the shortcomings as well, since they still should have longer circulation times than iodinebased small molecules due to less extravasation and larger size.

6.1.3 Expanding CT applications: targeted CT and SPCCT imaging
In our work, we demonstrated high accumulation of CeONP at the inflammation
site via passive targeting, despite its ultrasmall size. By designing our nanoparticles to
have initial sizes in the range of 5 to 200 nm, we can further promote the nanoparticle
accumulation to the diseased sites, such as tumor and inflammation, from the EPR
(enhanced permeability and retention) effect while escaping filtration by the RES organs.13
This will allow us to do targeted imaging with both CT and SPCCT, which can provide a
significant diagnostic value.
Targeted accumulation of nanoparticles via passive targeting for CT imaging has
been demonstrated in numerous studies so far, especially for tumor imaging. Findings
from a study by Smilowitz et al. suggests that it may be feasible for 15 nm AuNP to
accumulate in intracerebral tumor masses by injecting the nanoparticles intravenously as
determined from a rat glioma model.14 Another study by Ashton et al. also investigated
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and demonstrated that PEGylated, 30 nm AuNP can have high tumor accumulation via
passive targeting, although a large amount was also detected in liver and spleen.15 In
imaging with dual-energy CT, the authors also showed that iodinated contrast agents and
AuNP could be accurately separated from one another in vivo, validating that developing
nanoparticles from elements of high atomic number can lead to its material differentiation
from both iodine and soft tissues.
Targeted CT imaging can also benefit from the development of nanoparticles that
can actively target specific sites via functionalization of the nanoparticle surface with
targeting moieties, such as antibodies. binding to specific surface markers of tumor cells,
for example. A study by Hainfeld et al. demonstrated the feasibility of improving the
specificity of AuNP tumor accumulation by conjugating anti-Her2 antibody on 15 nm
AuNP. Upon intravenous injection, 16 % of AuNP accumulated to subcutaneously
inoculated human Her2+ breast tumors, which allowed successful detection of tumor
masses as small as 1.5 mm in thickness in micro-CT imaging.16 Peptides can also be
conjugated onto the nanoparticle surfaces to promote accumulation in the brain, which is
difficult to achieve due to the blood-brain barrier (BBB). Bao et al. conjugated angiopep-2
oligopeptide to facilitate BBB penetration of sub-5 nm CeONP via receptor-mediated
transport.17 The authors demonstrated that CeONP helped treat and protect the brain
against stroke induced by ischemic injury after crossing the BBB. Although CT imaging
was not performed in this specific example, the amount of accumulation in the brain was
enough that detection via CT imaging should be possible, which indicates the potential of
utilizing CeONP as a theranostic agent for disorders in the brain (e.g., Alzheimer’s and
Parkinson’s).
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Nanoparticle-guided targeted imaging is not limited to vascular contrast agents;
inflammation sites in the gastrointestinal tract can be detected in CT imaging by oral intake
of nanoparticle contrast agents. Naha et al. recently demonstrated that it is possible to
selectively image inflammation sites in the large intestines in colitis animal models with
dextran coated cerium oxide nanoparticles (Dex-CeNP).18 After an oral administration of
Dex-CeNP, a significant amount of the nanoparticles were accumulated in the colitis area
while the rest were cleared out from the body at 24 h post-injection, clearly visualizing the
inflammation site.

6.1.4 Expanding CT applications: cell tracking
Thus far, the use of CT for cell tracking has been limited, due in part to the low
sensitivity of CT, requiring internalization of high payloads in the cells (hundreds of pg/cell)
to produce sufficient attenuation for detection.19 This need for very high contrast agent
payloads increases the possibility of affecting cell viability or function, which could result
in misleading observations of cell migration and fate in the body. Furthermore, at such
high concentrations, contrast agent that is released from the cells or is degraded could
conceivably cause local tissue damage or systemic toxicity. Advances in nanoparticle
formulations for cell labeling, as well as cell labeling techniques, could help address these
issues. For example, techniques that have been used for labeling cells for other
modalities, such as electroporation or antibody attachment, have not been explored.
Furthermore, the development of new CT technology that allows better sensitivity and
specificity of detection would be beneficial, and such technologies are emerging. For
example, model-based iterative reconstruction techniques can suppress noise by a factor
of 10, considerably increasing the sensitivity of contrast agent detection.20 SPCCT
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imaging in cell tracking can also eliminate the need for laborious and error-prone pre- and
post-injection image analysis.21 In fact, the first study published a year ago used SPCCT
imaging for cell tracking and demonstrated that the labeled cells can be monitored in a
material-specific and quantitative manner with low detection limit of ~ 5000 cells in a
voxel.22
Recent studies of nanoparticle protein coronas and their effects on colloidal
stability

and

on

nanoparticle–cell

interaction

(i.e.,

internalization,

intracellular

transportation, cytotoxicity upon protein degradation) reveal the significance of
surrounding the nanoparticles with the “right” composition of proteins.23, 24 For cell tracking
purposes, protein corona-dependent nanoparticle–cell interaction can be crucial to
increase cellular uptake efficiency. Future studies may identify optimal protein
compositions to improve cellular uptake while minimizing disruption of cell functionality.
Improved uptake efficiency will also enable labeling of other non-phagocytic cells, besides
CAR-T cells, such as epithelial cells, endothelial cells, and fibroblasts, to broaden CT cell
tracking applications.
For CT cell tracking, AuNP are by far the most widely studied class of contrast
agent for labeling cells, due to biocompatibility, easily tailorable size and surface
chemistry, and high attenuation in CT.25 A potential issue for gold contrast agents is their
cost; however, when scaling up from the mouse, only around a gram of gold will be needed
for in vivo cell tracking in patients. Since the current price of gold is about $40/gram, CT
cell tracking contrast agents based on this element will be affordable. Nevertheless,
studies with labels synthesized from cheaper elements, such as cerium and tantalum,
would be of great interest and could further reduce the price of CT cell tracking, given that
we can formulate nanoparticles of high composition of the payload elements. Methods to
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achieve nanoparticle clearance would be a further design improvement. For example,
nanoparticles based on bismuth can be designed to degrade for eventual
excretion.26 SPCCT cell tracking will also allow simultaneous in vivo monitoring of multiple
cell types by labeling them using contrast agents with different K-edge energies, which
would further broaden the use of CT as a cell tracking imaging modality.

6.2 Future directions
6.2.1 Overview
In our work, we demonstrated the feasibility to develop specifically designed
nanoparticles as SPCCT and CT imaging contrast agents (chapter 2 and 3) and for CT
imaging applications of targeted imaging and cell tracking (chapter 3, 4, 5). Here, we
discuss how we could expand on the findings in this work for potential future projects and
the future direction of our CAR-T cell tracking work for in vivo monitoring.

6.2.2 Renally clearable CeONP as SPCCT contrast agents
As mentioned in our discussion, one of the biggest barriers in clinical translation of
nanoparticle-based CT contrast agents is potential cytotoxic effects from long-term
retention in the body.4 Our findings suggest that citric acid coated CeONP can be
effectively cleared from the body via the kidneys pathway, which can reduce long-term
cytotoxicity concerns. Moreover, cerium’s K-edge energy at 40.4 keV is sufficiently
distinguishable from that of iodine and is located in a high photon region, which results in
high CT contrast generation, as demonstrated in chapter 3 and 4. This makes CeONP
suitable for the development as SPCCT contrast agents. Moreover, cerium has
advantages other than its favorable K-edge energy over other heavy metal elements that
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are being investigated for contrast agent development (e.g., tantalum and ytterbium).
These are CeONP’s familiarity in biomedical research, its small core size, ease of bulk
synthesis and its versatility in surface coating (i.e., PEG, citric acid, polyacrylic acid,
ascorbic acid and other small molecules with carboxylic acid groups and hydroxy groups).
Its antioxidant and immunomodulatory effects can potentially be utilized in simultaneous
targeted CT imaging and treatment of inflammatory diseases, which include
atherosclerosis, stroke, injuries in various organs (e.g., liver, kidney and brain),
neurodegenerative diseases, as well as cancer. Using the capabilities of SPCCT imaging
in quantification of exogenous contrast agents, it may also be possible to predict the
outcome of CeONP treatment for aforementioned diseases from imaging alone.

6.2.3 In vivo CAR-T cell tracking in cancer immunotherapy
In our work in chapter 5, we have demonstrated the feasibility to label CAR-T cells
with AuNP without disrupting the cell viability and cytotoxic and inflammatory functions in
vitro. However, before moving the study forward to in vivo studies, we would like to confirm
that other cellular functions have not been disturbed significantly from AuNP labeling. We
will first evaluate proliferation, which a critical mechanism that is directly correlated to the
persistence and efficacy of the therapy. For this assessment, we will stain labeled and
unlabeled cells with carboxyfluorescine succinimidyl ester and be allowed to incubate for
1, 3 and 5 days in cell culture medium with CD3/CD28 Dynabeads. At each timepoint, the
cells will be collected and fixed for flow cytometry analysis. We will also assess migration
of the labeled cells to confirm that their ability to localize and penetrate the tumor mass is
not affected by examining the migratory behavior in Chemotaxis plate.
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In vivo tracking of AuNP-labeled CAR-T cells will be performed in a murine
orthotopic model of human breast cancer to test the feasibility using SPCCT imaging for
CAR-T cell tracking. Specifically, we will monitor 5E5 CAR-T cells (gifted by Dr. Avery
Posey) that target Tn-MUC1 (an aberrantly glycosylated MUC1 epitope) found in most
adenocarcinomas, including breast cancers.27,

28

The accuracy in differentiation and

quantification of AuNP labeled cells in SPCCT imaging will be assessed and corroborated
by ex vivo analyses such as ICP-OES and electron microscopy. The antitumor therapeutic
efficacy and cytotoxicity of labeled CAR-T cells also will be examined and correlated with
the biodistribution at different times points as determined by SPCCT imaging.

6.3 Concluding remarks
The findings in this work highlight some of the most important criteria in the
development of CT and SPCCT-specific contrast agents and the potential use of these
nanoparticles beyond blood pool contrast agents for broadening CT imaging applications.
Simultaneously, the use of numerous core elements, coating materials and encapsulating
components reflect the versatility of nanoparticles that will allow them to be continuously
explored for various CT imaging and other biomedical applications. With ever-growing
research interest in nanotechnology and newly emerging CT technologies, nanoparticles
will play a significant role in CT diagnostics in the future.
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